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ABSTRACT 
Scanning Electron Micrographs of soy cellulose (Emcosoy) 
particles were studied to further the understanding of the mor-
phology of the substance and thereby to increase the comprehension 
of how the excipient functions in tablet systems. 
Bulk swelling and water uptake were studied for Emcosoy, 
CLD II, corn Starch, and Ac-Di-Sol. Emcosoy had maximum swelling 
about 56%; followed by CLD II 49% and Ac-Di-Sol 9%. No swelling 
was observed in Corn Starch. An ideal disintegrant should perform 
uniformly in pH range of gastrointestinal tract in order to dis-
integrate the tablet. When Emcosoy and Ac-Di-Sol were tested 
against various pH values, there was no significant difference in 
swelling of these disintegrants. Since alcohol and sodium lauryl 
sulfate are often used as dissolution media, the effect of different 
concentrations were also observed on Emcosoy and Ac-Di-Sol. There 
was no significant effect. 
Another important preformulation test reported in this thesis 
is a comparative study of the viscosity of different concentrations 
of various disintegrants. When a tablet disintegrant reacts with 
water a gel may be formed. If the gel is too viscous, it impedes 
the water penetration in the tablet. Generally it can be said 
that the cellulose group of disintegrants (Ac-Di-Sol, CLD II and 
Emcosoy) had a viscous gel compared to starch group of disinte-
grants (Corn Starch, Explotab and Sta-Rx 1500). If the viscosity 
of the gel of starch group of disintegrants has to be arranged 
indescending order then Explotab is followed by Sta-Rx 1500 which 
is followed by corn starch. If the viscosity of the gel of 
ii 
cellulose group of disintegrants had to be arranged in descending 
order then CLD II is followed by Emcosoy which is followed by Ac-
Di-Sol. 
Plastic deformation and elasticity of various disintegrants 
were studied using a Universal Instron Testing Machine. High 
plastic deformation of the disintegrant particles, may be advant-
ageous since the deformed particles are " " energy-rich and that 
energy is released when the particles are exposed to water. The 
energy-rich particles probably swell more rapidly in water, unlike 
undeformed grains, which require more energy of swelling in order 
to well. Ac-Di-Sol particles have good plastic deformation compared 
to Emcosoy and Explotab particles. The three major mechanisms of 
( disintegrant action are : (i) swelling (ii) capillary action 
(wicking) and (iii) deformation. Emcosoy particles swell consid-
erably and they have good wicking effect, but they have poor plastic 
deformation. 
Following the performulation study, Emcosoy (soy cellulose) 
was compared with other disintegrants in about 45 formulations. 
About 100 dissolution profiles were obtained on various vitamin 
formulations using either Emcompress or Endex as the tablet matrix. 
Emcosoy is as effective a disintegrant as Ac-Di-Sol and very much 
more effective than Corn Starch. The results of preformulation 
study and formulation study strongly indicate that Emcosoy is a 
powerful tablet disintegrant which deserves careful consideration 
by all formulators . 
iii 
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I. INTRODUCTION 
There are two classes of drugs administered orally in tablet dos-
age form. These are: (1) insoluble drugs intended to exert a local 
effect in the gastrointestinal tract (such as many antacids and ab-
sorbents), and (2) soluble drugs intended to exert a systemic drug effect 
following their dissolution in the gut and subsequent absorption. 
In the case of drug products intended to exert a s ystemic effect, 
the design of a dosage form which rapidly disintegrates and dissolves 
may or may not be critical, depending on whether the drug is absorbed 
in the upper gastrointestinal tract or more generally throughout the 
intestinal tract. Because dosage forms must be designed to disintegrate 
or dissolve to release the drug in an available form at or above t he re-
gion of absorption in the gut, the design must also be based on the 
solubility properties of the drug at or above its absorption site. 
The present study covers the bioavailability consideration of 
the tablet as a dosage form, the disintegration process in general, and 
the information about a few widely accepted new disintegrants. The 
mechanism of disintegrant action will be discussed with the help of 
numerous references on the subject. 
( 
2 
1. Bioavailability Considerations: 
Bioavailability has been defined as the measurement of both 
the relative amount of an administered dose that reaches the general 
circulation (i.e., the extent of absorption of a given dose) and the 
rate at which this occurs (1 ). 
Some of the most impressive biopharmaceutical research with 
practical implications, published during the middle nineteen sixties, 
was that which demonstrated that different products of the same drug, 
although chemically identical in terms of drug content, could pro-
duce significantly different blood levels. For example, a study of the 
blood levels produced by different brands of tetracycline, all contain-
ing the same amount of drug, showed that the best brand gave blood 
levels ten times as high as the worst (2). 
Glazko, et al, showed that four different brands of 250 mg 
chloramphenicol capsules had different in vitro and in vivo bioavailability 
(3). Levy, et al, studied absorption and dissolution of two brands of 
phenytoin capsules and found that there was a significant 
difference in the bioavailability of the drug because each product 
differed from the other in disintegration and deaggregation (4). Bio-
availability has been a major problem for pharmaceutical dosage formu-
lators. The subject has drawn considerable attention since the 
nineteen fifties. Proctor, in 1862, stated: "The reason why 
( 
3 
pills occasionally pass through the stomach undissolved must be 
sought for in the state of the patient or in the composition of the 
pill, rather than in the nature of the coating . " (5). Proctor was 
not discussing enteric-coated pills, since the first enteric coating 
(Keratin) was described by Unna in 1884 -- 22 years later. Today, we 
realize Proctor's statement is only partially true, and that all three 
factors he discussed the state of the patient, the composition and 
the nature of the coating, may determine in vivo disintegration time 
and rate of dissolution and absorption of the drug. 
Unfortunately, Proctor's concern was not shared by other scientists. 
The need to quantify tablet disintegration by official standards was 
not recognized until just prior to World War II, and specifications for 
tablet disintegration did not appear in the USP until the fourteenth 
revision which was published in 1950. During the course of subsequent 
disintegration testing experiments, it was theorized and even-
tually proven that drug dissolution must follow tablet disintegration 
if bioavailability is to occur (6). 
The topic of bioavailability has now become of interest to govern-
ment; the FDA (Food and Drug Administration) has already issued speci-
fie regulations on bioavailability. 
When a drug in a dosage form is administered to a patient, the first 
steps in the sequence whereby the drug reaches the site of action are commonly 
disintegration and dissolution. The importance of these processes is 
( 
4 
understood when one realizes that solid oral dosage forms (mainly 
compressed tablets or hard gelatin capsules) are by far the most im-
portant dosage form class in terms of either doses administered per 
year or dollar value of drug dispensed (7). The process of disinte-
gration, dissolution, and absorption can be outlined as follows (8): 
Tablet or 
Capsule 
Disintegration) 
(1) 
Granules 
or 
Aggregates 
Deaggregation) 
(2) 
Dissolution 
(3) 
Drug in Solution 
(in vitro or in vivo) 
Drug in Blood, Other 
Fluids and Tissues 
Absorption 
(in vivo) 
Fine 
Particles 
(3) 
Before drugs can effectively pass through the gastrointestinal wall, 
they must be in solution. Drugs which are only sparingly soluble in 
the gastrointestinal content at or above their absorption site can have, as 
the controlling process affecting their absorption , the rate of drug 
solution in these fluids. In this type of system, the drug goes into 
solution at a slow rate, absorption occurs almost immediately and is 
( 
s 
not, therefore, the rate-limiting step. In one study, Nelson (9) 
correlated the blood level concentration of various theophylline salts 
with their dissolution rates. 
Drugswhich exert a systemic effect must dissolve as a prerequisite 
to effective drug absorption. The various processes of tablet making, 
including the aggregation of drug into granular particles, the use of 
binders, and the compaction of the system into a dense tablet, are all 
factors which militate against a rapid drug dissolution and absorption 
in the gastrointestinal tract. In considering, in a general manne~ the 
availability of drugs from various classes of dosage forms, drugs ad-
ministered in solution will usually produce the most available drug pro-
duct, provided that the drug does not precipj_tate in the stcraach or is not 
deactivated there. The second most available form of a therapeutic 
agent would be drug dispersed in a fine suspension, followed by micronized 
drug in capsule form, followed by uncoated tablets, with coated tab-
lets being the least bioavailable drug product in general. In formulat-
ing and designing drug products, as well as in considering methods of 
manufacture, the fact that the tablet dosage form is one of the least 
bioavailable forms (all other factors being equal) should be kept in 
mind (10). 
Many factors can affect drug dissolution rates from tablets; hence, 
possibly drug bioavailability , including the crystal size of the drug, 
tablet disintegration mechanisms and rates, the method of granulation, 
( 
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type and amount of granulating agent employed, type, amount and method 
of incorporation of disintegrants and lubricants, and other formulations 
and processing factors. 
Levy, et al (11), showed the effect of granule size upon the dis-
solution rate of salicylic acid. Salicylic acid of two mesh ranges 
containing 300 mg of aspirin and 60 mg of starch, were compressed at 
715 kg cm- 2 . The 60 to 80 mesh granules had better vitro bioavailability 
than 40 to 60 mesh granules. 
Lachman, ~al (12), studied the effect of crystal size and granule 
size on a delayed-action matrix using tripelennamine hydrochloride. He 
notes that while granule and crystal size both affected release rate, 
in this instance the crystal size played a greater role than granule 
size in dissolution rate. 
Paul, et al (13) showed that with nitrofurantoin there was an op-
timal average crystal size of about 150 mesh, which resulted in ade-
quate drug excretion (hence, absorption and efficacy), but minimized 
emesis. This exemplifies a situation in which too rapid drug dis-
solution in the stomach may produce nausea and emesis; an intermediate 
release rate reduced this effect while achieving adequate bioavail-
ability. 
Numerous accounts of the effect of particle size on dissolution 
rate of steroids have been reported. In one study, Campagna, ~al 
(14),showed that, in spite of good disintegration, therapeutic in-
efficacy of prednisone tablets could occur. 
( 
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As discussed above, bioavailability of the drug depends on many 
factors. The ensuing discussion will focus on the disintegration pro-
cess, disintegrants available, and the mechanism action of disinte-
grants. 
2. Disintegration of a Tablet and Disintegrants 
Complete tablet disintegr?tion is defined by NF XIII (15) as: 
II that state in which any residue of the tablet, except frag-
ments of insoluble coating, remaining on the screen is a soft mass hav-
ing no palpably firm core." This often makes tablet disintegration a 
necessary first step to achieve rapid availability of the active ingre-
dient(s). The importance of tablet disintegration was recognized as 
early as 1879, when a patent recommended that pills be perforated to 
admit gastric juice for better disintegration (16). 
Reasons for Measuring Disintegration Times and Rates of Dis-
solution 
(i) For research purposes to elucidate the mechanism involved 
in the processes and to determine the relative importance 
of the various variablesinvolved in the process of dis-
integration, deaggregation, and dissolution. 
(ii) For developmental purposes to guide the pharmaceutical for-
mulator in the preparation of optimum dosage forms of 
drugs for clinical trial. 
8 
(iii) For control purposes to ensure that a given pharmaceutical 
( 
product is essentially uniform from lot to lot. 
(iv) For predictive purposes so that one may estimate rate(s) 
of absorption in man from measurement of disintegration 
time and/or rates of dissolution in vitro. Such pre-
dieting requires careful correlation of in vitro and in vivo 
results. 
Our discussion of disintegration will be confined to uncoated tablets 
designed to release all the active ingredient(s) rapidly. 
The disintegration of a tablet depends on compression force, tab-
let hardness,propertiesof fillers and active ingredients, properties of 
binders,propertiesand concentration of disintegrant and the properties of 
lubricants. All these factors play an important role in tablet dis-
integration. If we keep other factors identical (compressive force, 
fillers, active ingredient binders, and lubricant) in two formulations 
but select two different disintegrants at the same concentration for 
these two formulations, the in vitro bioavailability will entirely depend 
on the quality of the disintegrants. The drug will be released quickly 
from a tablet which disintegrates faster because it has better disinte-
grants. Thus, the disintegrants play a role in the disintegration 
process. The ensuing discussion will focus on different disintegrants. 
( 
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Disintegrant is a term applied to substance added to a tablet 
granulation for the purpose of causing the compressed tablet to break 
apart when placed into an aqueous environment. The disintegrant in a 
tablet formula may be considered as a dispersing agent for the dry com-
pacted tablet mass in the gastric milieu. Ideally, it should cause the 
tablet to disrupt not only into the granulated form which it was com-
pressed, but also into the powder particles from which the granulation 
was prepared. 
The function of the disintegrant is, in effect, to counteract the 
action of the tablet bindersand the physical forces of compression 
necessary to form the tablet. The stronger the effect of the binder, 
the more efficient must be the disrupting effect of the disintegrant 
in order to release the active ingredient in the gastrointestinal tract (17). 
There are two methods used for incorporating disintegrating agents 
into tablets. These methods are called external addition and internal 
addition. The most common method is the external addition method in 
which the disintegrant is added to the sized granulation with mixing 
just prior to compression. In the internal addition method, the dis-
integrant is mixed with other powders before wetting the powder mix-
ture with the granulating solution. Thus, the disintegrant is incor-
porated within the granule. When this method is used, part of the dis-
integrant is added internally and part by external addition. Many ex-
perts believe that use of the two-step method usually produces better and 
more complete disintegration than the usual method of adding the dis-
( 
( 
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integrant to the granulation surface only. 
Six basic categories of disintegrants have been described: starches, 
clays, celluloses, algins, gums, and miscellaneous. Many disinte-
grants have also been shown to possess binder or adhesive properties. 
Since disintegration is the opposite operation to granulation (agglo-
meration) and the subsequent formation of strong compacts, one must 
carefully weigh these two phenomena when designing a tablet (18). 
Formulators have tried a number of materials as tablet disintegrants 
with varying degrees of success. Lowenthal tabulated all the disinte-
grants with their pertinent references in a review article of "Dis-
integration of Tablet," in Journal £f Pharmaceutical Sciences (19). 
In the past six to seven years, exciting developments have occurred 
in the area of tablet disintegrants. A nurr,ber of new disintegrants 
have been marketed in this period. Attention will be focused on 
these ''super disintegrants~ as they are called, because of their re-
markable quality as disintegrants. 
(i) Direct-Compression Starch: 
One of the most significant modifications of starch for 
direct-compression tableting came with the advent of starch 
1500 (Colorion, Inc., West Point, Pennsylvania, originally 
marketed by A.E. Staley Co. as Sta-Rx 1500). The material is 
prepared by subjecting ordinary corn starch to physical com-
pression or shear in high moisture conditions; that prepara-
tion causes both an increase in temperature and a partial 
( 
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gelatinization of some of the starch. Direct compression 
starch retains its disintegrating characteristics despite its 
partial pregelatinization. While plain starch acts as a dis-
integrant primarily through wicking action and the elastic re-
covery of compression-deformed grains when they are wetted, 
Starch 1500 also acts by truly swelling in the presence of 
moisture. 
(ii) Sodium Carboxymethyl Starch: 
Another of the modifications of starch aimed at improving 
its disintegration properties involves chemical changes that 
form a low-substituted sodium carboxymethyl starch. The addi-
tion of the carboxymethyl groups makes the starch grains more 
hydrophilic -- but not completely water soluble. The process 
also causes a two- to three-fold increase in the size of the 
starch grains. A minimum of 3% to 4% sodium carboxymethyl 
starch is required for most formulations. The sodium car-
boxymethyl starch is marketed as Primojel HV (Generichem Corp., 
Little Falls, New Jersey, and Explotab, Edward Mendell Co., 
Carmel, New York). 
(iii) Cross-Linked Sodium Carboxymethyl Cellulose: 
Internally cross-linked carboxymethyl cellulose fibers 
have been introduced commercially -- as Ac-Di-Sol (FMC Corp., 
Philadelphia, Pennsylvania), and as CLD Cellulose (Buckeye 
( 
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Cellulose Corp., Memphis, Tennessee), for use as tablet dis-
integrants. The cross-linking greatly reduces water solubility 
while still permitting the material to swell and absorb many 
times its weight in water without losing individual fiber 
integrity. Cross-linked sodium carboxymethyl cellulose may 
be used as a tablet disintegrant in concentrations as low as 
1%, although 2% is recommended for tablets made by direct 
compression, and a 3% level for those made by wet granulation. 
(iv) Cross-Linked Polyvinylpyrolidone: 
Cross-linked polyvinylpyrolidone (PVP) is a homopolymer 
of N-vinyl-d-pyrolidene and has been marketed as Polyplasdone-
XL (GAF Corp., New York, New York). Because of its high mole-
cular weight and cross-linked structure, it is insoluble in 
water but is still very hydrophilic. The particles of PVP are 
porous in nature. As water is absorbed into the porous 
structure of the agglomerates, the lattice structure of poly-
mer expands, causing high stress on surrounding tablet components. 
The porous nature of the particles provides intraparticulate 
wicking of water. Like cross-linked carboxymethyl cellulose, 
cross-linked PVP has the ability to shrink to its original 
particle size when dried and then expand again when rewetted. 
Both cross-linked carboxymethyl cellulose and cross-linked PVP 
would thus appear to be effective disintegrants in tablets made 
by wet granulation, as well as in those produced by direct 
( 
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compression. 
Shangraw, et al, discussed the properties of these disinte-
grants in detail with their scanning electron micrographs in the 
Pharmaceutical Technology article (20) . 
3. Mechanism of Disintegrant Action: 
For various disintegrants, various theories relating to 
their disintegration actions have been proposed; 
but none has truly explained the disintegrant properties of all the 
agents. The three major mechanisms of action are (i) swelling, (ii) 
porosity and capillary action (wicking), and (iii) deformation. 
' , 
J 
(i) Swelling: 
Rank orders of decrease in swelling of various starches 
under different conditions were described as: wheat, corn, 
potato, arrowroot, and rice (21); potato, corn and wheat(22); 
and potato, wheat, and rice (23). 
Tablets made with low pressure have high porosity, and 
hence, too much space. When starch swells, no pressure is 
exerted; therefore, disintegration is slow. Medium pressure 
allows just enough space so that when the starch swells, it 
exerts pressure on the granules to cause disintegration. High 
pressure, producing low porosity, decreases the ability of 
fluid to enter; so, disintegration is again slow (24, 25). 
Starch swelling was claimed to be dependent upon amylase and 
( 
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arnylopectin content; the amylopectin expands, and the amylase 
gives osmotic pressure (26) . 
Borzenou and Nesmiyan (27) reported that the degree of swell-
ing of acid carboxymethyl cellulose was 220%; of sodium carboxy-
methyl cellulose, 400%; of sodium alginate, 450%: and of ultra-
amylopectin, 1100%. A mixture of starch with 0.1% ultra-araylo-
pectin gave maximum swelling, while acid carboxymethyl cellulose -
starch mixture (3: 97) gave the second largest swelling. A mixture of 
ultraamylopectin-starch (2:97) as 10% of a formulation gave the 
best disintegration times, while acid carboxymethyl cellulose -
starch (3:97) gave the second best disintegrant times. It was 
suggested that starch forms the capillaries, and the ultra-
amylopectin acts as a swelling agent (28). 
Many substances swell to a greater degree than the starches, 
but are poorer disintegrants. Amylase does not swell but has 
been stated to cause good disintegration (29). Although starch 
grains swell in water according to some views which I do 
not share, the rate and extent of swelling is still debated 
(30-32). 
Whenever swelling of disintegrant particles take place with 
great force, it overcomes the adhesiveness of other ingredients 
in a tablet and causes the tablet to fall to powder. 
(ii) Porosity and Capillary Action (Wicking): 
Porosity of tablets has been studied with increasing fre-
15 
quency in recent years, using a variety of materials and numerous ( 
experimental methods. Porosity, void space, and pore size de-
crease as pressure increases (33-46). Potato and corn starches 
increase mean pore diameters and porosity (47-50). Pore size and 
volume decrease as the moisture content of starch increases. 
The rate of penetration of fluids into a tablet is pro-
portional to mean pore diameter or porosity (51-52); corn and 
starches increase penetration of fluids into tablets. Permea-
bility of tablet decreases as pressure increases. The effect of 
starch on porosity may be due to its poor ability to bond and 
compress (52). In 1955, Curlin reported that although aspirin tab-
lets containing starch disintegrated in 15 seconds, starch grains 
I 
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were not swollen; nevertheless, a drop of dye solution placed on 
the tablet penetrated rapidly. He suggested that the disinte-
grating action of starch was due to capillary action, rather than 
to swelling (53). 
Wicking is due to capillarity of fibers. Stiff fibers of uni-
form structure and resistance to collapse are required for good 
wicking. The fibers should have zero contact angle and should not 
swell (54). This would appear to rule out any wicking effect 
due to starch or cellulose fibers. 
( 
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The existence of pores or capillaries is not the complete 
answer to the mechanism of action of disintegrants, because 
semipolar and nonpolar fluids penetr~te into tablets (55), yet 
do not cause the tablets to break. Also, tablets do disinte-
grate with minimum porosity (56). 
(iii) Deformation: 
Plastic deformation of starch grains under high pressure 
has been reported by a number of investigators (57). Starch 
grains are generally thought to be elastic; therefore, any 
grains that are deformed under pressure tend to return to their 
original shape and size when the pressure is removed. However, 
it has been suggested that compression may cause more permanent 
deformation that the deformed starch grains are energy rich and 
that this energy is released when the grains are exposed to 
water (58). The energy-rich starch grains swell rapidly in water, 
unlike undeformed grains, which require more heat in order to 
swell. 
The various mechanism of disintegration action discussed un-
der a separate heading, interrelationships, probably occur in al-
most all tablet formulations. 
17 
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B. 1. Objective and Justification for the Present Study: 
As discussed earlier, tablet disintegration has been increasingly 
viewed as an important factor in formulating pharmaceutical systems. 
Mechanisms by which tablet disintegrants function have been investi-
gated. 
The current concern about bioavailability of drug products has 
made formulators very selective in the use of disintegrants. The 
United States Pharmacopoeia is presently considering a radical exten-
sion of dissolution test requirements to most conventional tablets and 
capsules, and thus a number of formulators are now re-evaluating their 
formulations to see whether it is now appropriate to alter the iden-
tity or quantity of disintegrant (59) . 
The pharmaceutical industry has been using corn starch and guar 
gum extensively as tablet disintegrants for many years. Both dis-
I 
integrants are natural source materials, but their function as a tab-
let disintegrant are not satisfactory. There is, however, a demand 
from certain segments of the pharmaceutical industry, particularly 
those concerned with vitamin formulations, which require a powerful 
disintegrant of natural origin. 
Soy cellulose (Emcosoy), is an all-natural source material, de-
rived from defatted soy beans by a special process. It contains no 
sugar or starch, and it has been given GRAS status (Generally Regarded 
( 
As Safe) by the United States Food and Drug Administration (60). 
Many formulators are not aware of the potential of this material 
because of the lack of authentic and extensive study . It is hoped 
that the present study will provide a reliable evaluation of soy 
cellulose (Emcosoy) as an effective substitute for corn starch and 
guar gum. 
18 
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II . EXPERTMENTAL 
A. Equipment: 
The following items were used: 
Mettler KS Balance, Mettler Instrument Corp. , Hightstown, NJ. 
Mettler n3 Balance, Mettler Instrument Corp., Hightstown, NJ. 
Sieve Shaker, Fisher Wheeler, New Britian, CT. 
Brookfield Synchro Lectic Viscometer, Model RVT, Stoughton, MA. 
(Food Science and Nutrition Department, URI). 
Instron Universal Testing Instrument, Instron Corporation, 
Canton, HA. (Department of Mechanical Engineering, 
Wales, URI). 
Scanning Electron Hicroscope, Cambridge Instruments, Cambridge, 
England (Graduate School of Oceanography, URI). 
Twin Shell Dry Blender, Patterson Kelly, East Strousburg, PA. 
U-tube type water uptake apparatus (Two water reservoirs are 
joined by rubber tube; one is to measure the swelling of 
disintegrant, and the other to measure the water uptake. 
(Fig. ) . · 
Stokes Rotary B2 Tablet Press, Pennwault Corporation, Warminster, 
PA. 
Erweka Hardness Tester, Erweka G. m. b. H. Frankfurt, West 
Germany. 
Roche Friabilator, Erweka G. m. b. H. Frankfurt, West Germany. 
U.S.P. Disintegration Apparatus, Scientific Glass Apparatus Co., 
Bloomfield, NJ. 
U.S.P. Basket Dissolution Apparatus, Precision Scientific Co., 
Chicago, IL. 
Dissograph (programmable automated dissolution test analyzer), 
Hanson Research Corp., Northridge, CA. 
\ 
Perkin Elmer Hitachi 200 Spectrophotometer with recorder, 
Perkin Elmer Corporation, Norwalk, CT. 
Hewlett Packard Calculator with plotter, Hewlett Packard 
Calculator Products Division, Loveland, CO. 
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Computer, Itel As/5, running IBM OS/MVT with HASP II, Ver-
sion 3. (URI Academic Computer Center, Tyler Hall, URI, 
Kingston, RI 02881). 
B. 
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Haterials: 
The following chemicals were obtained from Amend Drug and 
Chemical Company, Irvington, NJ: 
Riboflavin USP, Lot D 14687 M 23; 
Niacin USP Lot D 15492 R 19; 
Ascorbic Acid USP Lot D 15128023; 
Pyridoxine Hydrochloride USP Lot F 15949B24; 
Corn Starch USP Lot C 712551; 
Sodium Lauryl Sulfate USP Lot D 14148 I 01. 
The following materials were obtained from Edward Mendell 
Company, Carmel, NJ: 
Calcium Phosphate Dihydrate (Emcompress) Lot No. 9229; 
Soy Cellulose (Emcosoy) Lot No. SY 131 X; 
Emdex (90 to 92% Dextrose + 3 to 5% Y.i.altose + Higher Glu-
cose) V 15; 
Sodium Starch Glycolate (Emplotab) Lot No. C 192 X; 
Other materials used in this study included: 
Carmellose (Type A) ~c-Di-Sol) - Lot No. 6379. FMC Corp., 
Philadelphia, PA. 
Carmellose (Type B) (CLD II) - Lot No. 1026 BP. Buckeye 
Cellulose Corp. , Memphis, TN. 
Granulated Ascorbic Acid - Lot No. 230020; Roche Laboratories, 
Nutley, NJ. 
Magnesium Stearate - Lot No. N 49483; Ruger Chemical Company, 
Inc., Irvington, NJ. 
( 
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Stearic Acid, Ruger Chemical Company, Inc., Irvington, NJ. 
Sta-Rx 1500 (modified starch) - Colordon, Inc., West Point, 
PA. 
Polyplasdone XL (Cross-linked polyvinylpyrrolidone), GAF 
Corporation, NY. 
NOTE: Emcompress, Emdex, Emcosoy, Ac-Di-Sol, CLD II, Explotab, Poly-
plasdone XL, and Sta-Rx 1500 are trade names. Trade names are 
used throughout the thesis due to their familiarity and con-
venience. 
( 
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c. Methods: 
There are several tests which can be used to evaluate disintegrants 
before using them in actual formulations. No one test is perfect; each 
has its advantages and disadvantages. The behavior of disintegrants 
alone could be vastly different compared to their behavior in compressed 
tablets. Some of these tests may, however, be useful as the basis of a 
raw material specification designed to control lot-to-lot variation. 
( 59). 
1. Scanning Electron Micrographs: 
The role of particle morphology(size, shape and composition) 
in the production of tablets has long been discussed. This theo-
retical effort has found an a ·lly in scanning electron microscopy 
(SEM), which has made it possible to obtain direct photographs of 
tableting excipients and finished compacts. This instrument pro-
vides scanning electron micrographs of a range of disintegrating 
agents, lubricants, and glidants in an attempt to further the un-
derstanding of the morphology of those substances and thereby to 
increase the comprehension of how the excipients function in 
tablet systems. ( 6 ). 
Fig. ( 1 ) depicts the principle of the scanning electron 
microscope. The entire procedure was carried out as follows: 
a. An adhesive was placed on a metal stub, which was 
coated with gold or cadmium. 
b. A few disintegrant particles were sprinkled on the stub. 
( Working Principle of Scanning Electron Microscope 
I 
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Electron gun 
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Detector 
Fig. 1 
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c. The stub was placed in electron microscope and photo-
graphs were taken. The Emcosoy particles were magnified 
200, 1070, 1100, and 2200 times to its original size. 
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The scanning electron microscope helps in elucidating the struc-
ture of individual disintegrant particles by magnifying them to 
thousands of times their original size (Fig. 4 , 5). (Note: The 
scanning electron microscopy work was performed by Mr. Donald Scales 
of the URI Graduate School of Oceanography). 
2. Bulk Swelling and Water Uptake: 
One relatively simple test used by many groups involved in 
the evaluation of tablet disintegrants is the quantification of 
the interaction of a bulk powder bed, composed of pure disinte-
grant, with water. There are several types of apparatus which 
can be used for this purpose. The one used in this study con-
sistedof a calibrated glass reservoir (containing water or other 
approp~iate fluid), .connected at its base by a U-tube to a se-
cond glass reservoir which contained the disintegrant powder 
(Fig. 2). Values sought were the decrease in volume of water 
in the reservoir and the increase in size of the powder bed (the 
two values are not necessarily identical) as a function of time. 
The percentage of swelling and the percentage of water uptake 
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% Swelling (1) 
where s0 is the disintegrant level in the tube at time zero, 
and St is the disintegrant level in the tube at any time t. 
100 ( (V - V )/V 
t 0 0 
% Hater Uptake =~~~~~~~~~~~ 
v 
0 
(2) 
where v0 is the water level in the calibrated reservoir 
at time zero, 
and Vt is the water level in the calibrated reservoir at 
time t. 
Percentage of swelling and water uptake were plotted versus 
time. This test is helpful in determining the ease and extent of 
' 
bulk powder interaction with water ( 61 ). 
The disintegrants used for this test were Emcosoy, Ac-Di-Sol, 
corn starch, and CLD II. The solvents were distilled water, 
ethanol/water mixtures, and sodium lauryl sulfate solutions. 
Air pressure was used to remove air bubbles from the lower 
funnel shape portion of the reservoir. The apparatus was left 
undisturbed for half an hour, so the water levels in both reser-
voirs remained constant. The readings were taken initially at 
short intervals, but later at an interval of twenty minutes. 
( 
( 
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3. Water Penetration of Disintegrants: 
Although the mechanism of disintegration is very complicated 
and has not been completely determined (40), the penetration of 
liquid into a tablet is the first step in the process of tablet 
disintegration. 
In this test the water penetration in various disintegrants was 
compared. The penetration of a liquid into a capillary is expressed 
by the following equation: 
R y Cos 6 t (3) 
12 = 
2 n 
Where: L is the penetrated length of capillary 
R is the radius of capillary 
y is the surface tension of liquid 
n is the viscosity of solution 
e is the angle or contact 
t is the time in seconds 
The penetrated length of powder bed can be seen visually in a 
calibrated tube. Then the reading, which is in milliliters, can be 
converted into centimeters by multiplying it by 2.1, since 1 ml 
2.1 cm. 
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L2 
RyCose (4) 
= 
2n 
12 kt (5) 
Where: k = RyCose which is called penetrating rate constant. 
k varies with materials used; i.e., it depends on the average 
radius of void space R, and contact angle e . 
The water temperature was about 22 ~ 1°C. The tube containing 
disintegrants was tapped ten times in all the cases. The water 
penetration was measured at intervals of twenty minutes. vs. 
t was plotted. 
4. Energy of Wetting: 
( Penetration rate of water into disintegrant bed also depends on 
temperature of water ( 55 ). An attempt was made to find out approxi-
mate energy of wetting of Emcosoy. The water temperatures were 22, 
0 29.2, and 37 C respectively. The temperature range was kept as wide 
as possible; temperatures included storage condition 
(room temperature), as well as temperatures of the mediums (for dis-
integration and dissolution tests). 
The entire experiment was carried out the same way as discussed 
under water penetration of disintegrants. Nogami, et al, derived an 
equation from Andrade's equation: 
n = Ae E/RT ( 6) 
( 
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Where E is the activation energy of viscosity, A the constant, and 
R the gas constant. On the other hand, the adhesion tension, yCose, de-
pends on temperature at a constant pressure P, as: 
yCos8- T 
( orcos8) 
( ClT ) 
( 7) 
p 
Where 6H is the heat wetting. If systems are not disturbed during 
the wetting process, 6H is independent of temperature. In this experi-
ment, pressure p is considered constant; solving above equation. 
y Cose = 6H CT (8) 
is obtained, where C is the positive constant; combining all above-
mentioned equations: 
( 6H - CT) E (9) k y e- /RT 
2A 
Since generally 6H/CT is coming between one and two, taking logarithm of 
equation, approximating log (6H/CT - 1) to 6H/CT + C" 
Log k = a p (10) 
T RT 
Where a. = Log c + c'T'l , B = E - R 6H 
c 
L2 = kt we discussed under water penetration of disintegrants. 
We can obtain value of k from slope of each straight line and then 
·; 1 plotting log k T vs. _ • Slope = SIR we can calculate the value of S --
energy of wetting by ~ultiplying slope by R (J.987 cal. deg.-l mole-1). 
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5. Wetting and Drying of Disintegrants: 
( The effect of wetting and drying was observed on Emcosoy . 
Emcosoy was wetted with excess of water in a petri dish (diameter 
22 cm). Then the first batch was dried at room temperature (21 C) ,; 
second and third batches were dried inside the oven at 40C and 
and 60C respectively. The cake-like mass that formed on drying 
was reduced to fine particles by using a Fitzpatrick Comminuting 
Machine. The sieve, #00, was placed at collecting end of machine. 
The particles received through the "OO" sieve passed through the 
100 mesh (U.S. Standard) screen. 
The bulk swelling was determined by using the D-tube-type ap-
paratus for all the batches. The batch which was deemed most 
promising in all respects was -compressed as formulation IV. 
Tablets from· both batches were made at identical press 
settings,using original Emcosoy for comparison purposes. Tab-
lets from both batches were compared for weight, thickness, 
hardness, and disintegration time. 
6. Aqueous Dispersion: 
Emcosoy (2g) was dispersed in 100 ml of dilute hydrochloric 
acid solution (1in100, pH .70), and in 100 ml water in two 
measuring cylinders. It was left overnight with periodic stirring 
initially. The disintegrant settled at the bottom, the volume of 
disintegrant was measured in the beginning and at the end to find 
out the percentage of swelling. 
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The measuring cylinder provides larger room for the swelling 
of disintegrant particles, compared to calibrated .tube used in 
bulk swelling study. The medium was kept acidic to simulate 
effect of gastric pH on the swelling of the disintegrant. In 
another cylinder, the effect of water on swelling of disintegrant 
was observed. The percentage of swelling of disintegrant in neutral 
and acidic medium was compared. 
7. Comparative Study of the Viscosity of Different Strength 
Solutions on Various Disintegrants: 
Determination of the viscosity of solution or gel (disintegrant 
and solvent interaction) is important because: 
a. a viscous gel that sometimes forms on the surface of 
a disintegrating tablet due to solvent disintegrant 
interaction, impedes the further penetration of water 
into the tablet and thus prolongs the process of dis-
integration. 
b. The contribution of disintegrant in increasing the vis-
cosity of dissolution medium is important. Increase in 
viscosity increases the diffusion layer thickness value 
(Diffusion Layer Model) and thus slows down the dis-
solution rate. According to Noyes-Whitney Law: 
de KDS (Cs - C) (11) 
= 
dt Vh 
( 
Where: de/ is the rate at which drug is dissolving 
dt 
K is the Constant 
D is the Diffusion Coefficient 
s is the Surface Area of Particle 
V is the Volume of Solution 
h is the Thickness of Diffusion Layer 
(Cs-C) is the Cone. Gradient 
The equation can be further simplified: 
de 
dt 
K's (Cs - C) 
K's Cs 
KD 
Where K = -
Vh 
Where C is very small 
Particle Cs h C 
---
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Stirring reduces the value of h. If we have two solutions, A 
and B, A has a higher viscosity than B; then stirring will reduce 
the value of h in B easily and dissolution process will be en-
hanced. Thus, viscosity plays an important role in dissolution 
and ultimately in the bioavailability of the product. Although 
the overall impact may be small, it still may be an important 
factor. 
Solutions of different disintegrants were prepared from 2% 
to 16% by dispersing the disintegrant in water at 37°c. The resulting 
solutior~ were stirred with glass rod to mix the disintegrant and 
water thoroughly. The viscosity of the solution was determined by 
using a Brookfield viscometer, 
( 
( 
Shear rate (y): 2~R·rps 
0 
Shear Stress (T): F~ 
Viscosity = T/y (Poise) 
rps = rpm/60 
R is the radius in the spindle. 
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(12) 
(13) 
o is the portion of the solution which is subjected to stress. 
Fis 7,187 dyne-cm 
L is the height of spindle in a solution. 
% is the torque reading. 
Spindle: Big to small (1 to 7) 
Twenty, fifty, and a hundred rpm were used. The dial reading 
was taken when the pointer had completed one full return. 
The easiest method of calculating viscosity is to use the Brook-
field Viscometer Scale, which is applicable if the 
experimental conditions comply with those mentioned by the manu-
facturer. In this study, the scale was used because the experi-
mental conditions were well within the realm of those mentioned 
by the manufacturer. 
The rheological pattern of the different disintegrant solu-
tion was studied. Their viscosities were compared. 
8. Y..aximum Hydration Capacity of Various Disintegrants: 
The concentration of disintegrant in a hundred milliliter was 
increased to a point where there was not enough water to wet all 
( 
( 
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the disintegrant particles. The solution was stirred with a glass 
rod to disperse the disintegrant. Maximum hydration capacity of 
Ac-Di-Sol, Emcosoy and CLD II was compared. 
9. Emcosoy-Sieve Analysis: 
Sieving is a commonly used method for measuring particle size 
distribution because it is inexpensive, simple, and rapid with 
little variation between operators, provided that similar procedure 
are followed. The procedure involves the mechanical shaking of a 
sample through a series of successive smaller sieves, and the 
weighing of the portion of the sample retained on each sieve. The 
type of motion influences sieving vibratory motion is most efficient, 
followed successively by side-top motion, bottom-top motion, rotary 
motion with top, and rotary motion. 
One hundred gram powder was placed on the top sieve, and the mechani-
cal shaking was continued for 30 minutes. The portion of the sample re-
tained on each sieve was weighed. The results obtained were tabu-
lated (Table xxV), and the average diameter of Emcosoy particle was 
calculated as shown in the table. 
10. Plastic Deformation and Elasticity of Various Disintegrants: 
Plastic deformation of starch grains under high pressure has 
been reported by a number of investigators ( 62, 63). Starch 
grains are generally thought to be elastic; in fact, most materials 
are elastic up to a certain extent. Elastic grains deformed under 
( 
( 
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pressure tend to return to their original shape and size when the 
deforming pressure is removed. However, it has been suggested 
that compression may cause more permanent deformation, which is 
eermed, "plastic deformation." These deformed starch grains are 
energy rich and this energy is released when the grains are ex-
posed to water ( 64 ). The energy-rich starch grains swell 
rapidly in water, unlike undeformed grains, which require more 
heat in order . to swell. Recently published electron photomicro-
graphs of potassium chloride and aspirin tablets clearly show de-
formed starch grains both on the external surf aces and in cross-
sections of tablets ( 63). These grains returned to their 
original shape when the tablets were exposed to moisture. 
We can classify various disintegrant particles into two 
categories: those permanently deformed by the compression 
(in other words, these particles are nonelastic particles); and 
those much less permanently deformed by the compression (elastic 
particles). 
In the past, the scanning electron microscope was used for gaining 
insight into the behavior of solids under compression. It is a 
powerful tool; however, it does not express elasticity in any 
arithmetic numbers, so it is almost impossible to compare plastic 
deformation elasticities of various disintegrants. 
( 
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The Instron Universal Testing Instrument, which is widely used 
in food science to study textural properties of cooked comminuted 
fish muscle ( 65 ), was used. This equipment is also used in 
textile industries, packaging industries, and rubber industries. 
It evaluates properties in terms of shear strength, compressive 
strength, modules of elasticity, resilience, and puncture strength 
of the material. 
This machine was used in the present study for determining 
deformation of the disintegrants, as well as compressive force need-
ed to achieve those deformations. Modules of elasticity, percentage . 
of plastic deformations and percentage of recovery were also calcu-
lated. A favaccessories were designed to use the machine for handl-
ing powder-like materials. 
The disintegrant was placed in a cylinder which had one end left 
open; the other end was closed by a removable bottom. These re-
·movable bottoms were designed to facilitate tile re-
moval of compressed powder. The piston, which was attached to a 
load cell, could move upward or downward freely, into the cylinder 
through the open end. The load cell has a capacity to apply com-
pressive force up to 20,000 lbs. The load cell was connected to 
controlling panels which had a digital dial that showed the dis-
tance traveled by the load cell . It also had switches which re-
gulated upward or downward movement of a loading cell, as well as 
the distance that would be traveled by the loading cell. There 
( 
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was a dial which could be rotated to regulate the compressive 
force of the loading cell. The movement of the loading cell with 
the piston could be synchronized with the movement of the chart 
paper. 
The chart paper had ten big divisions, and each big division 
was divided into ten small divisions; so the total number of small 
divisions was one hundred. A mobile recorder pen moved along the 
base line of the paper, with the movement of piston. Whenthe piston 
applied pressure on the disintegrant particles, the pen moved on the 
calibrated chart paper; so by counting the small divisions, one 
can determine the pressure applied by the piston. 
The piston can move down and up once or more times; that· 
makes it possible to apply single compression or cyclic compres-
sion. 
The data was interpreted as follows: 
Deformation distance Load Cell Chart 
5 in/min. x 1/2 min/in. 
= .25 load cell/chart 
Modulus of Elasticity= 
Compressive Stress 
Corresponding Strain 
F/A 
6L/L 
(15) 
( 
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Where F is Compressive Force 
A is the area of the piston which comes in contact 
with powder. 
61 is the reduction in the height of disintegrant. 
1 is the original height of disintegrant in a cylinder. 
Now, for example, if pen travelled 9.2 divisions on chart paper: 
25 x 9.8 
10 
0.23 inch (61) 
.23 = .102 
= 
1 2.25 
F 
A 
= 
Compressive Force 
Area of Piston ( E2) 
= 2.85 x 103 (From Chart) 
Elasticity 
3.14 x (0.55)2 
2850 = 956.38 lb/in2 
F/A 
6 1/1 
956.38 lb/in2 
.1022 
9357.93 lb/in2 
How to achieve desired deformation (if you want to attempt 10% 
deformation). 
The height of disintegrant in a cylinder is 2 . 25 inches. 
10% of this height = 0.23 inch. 
When the piston touched the powder in a cylinder, the reading was 
adjusted to zero. Then the distance 0.23 inch (as calculated above) 
would be set on the scale and the ;:down" switch would be pressed. The pis-
( 
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ton would travel 0.25 inch in a powder bed, and the compressive 
force needed to travel that distance would be recorded on a chart 
paper. 10%, 20%, and sometimes 40% deformations were attempted. 
Plastic Deformation: 
Sample Height 
D1 is the distance travelled by piston during cycle one. 
D3 is the distance travelled by piston during third cycle. 
and D3 = 11 div. on chart, 
D3 = 11 x .25" .275 10 div. 
% Plastic deformation =~~~~~~ 
Sample Height 
% Recovery 20-12.22 
= 7.78% 
.275 0 x 100 
2.25 
12.22% 
The height of the disintegrants were adjusted to 2.25 inch af-
ter tapping. Modulus of elasticity values at various attempted de-
formations and the compressive force needed to achieve that deforma-
tion were compared for various disintegrants. Percentages of plas-
tic deformation and percentages of recovery were also compared for 
various disintegrants. 
( 
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11. Formulations: 
Formula I: Riboflavin 0.57% 
Pyridoxine hydrochloride 0.86% 
Niacin 5.70% 
Ascorbic acid 17.10% 
Disintegrant* 0.5% or 1.0% 
or 3.0% 
Stearic acid 2.5% 
Emcompress or Emdex ad 100% 
Tablet weight 350 mg. 
Formula II: Pyridoxine hydrochloride 5.0% 
Disintegrant* 0.5% or 1.0% 
or 2.0% or 3.0% 
Magnesium stearate 0.5% 
Emcompress or Emdex ad 100% 
Tablet weight 200 mg 
Formula III: Ascorbic acid 25.0% 
Disintegrant* 0.5% or 1.0% 
or 2.0% or 3.0% 
Stearic acid 2.5% 
Emcompress ad 100% 
Tablet weight 400 mg. 
*Emcosoy, Explotab, Ac-Di-Sol and Corn Starch were used as disinte-
grants. 
( 
Formula IV: Hydrochlorothiazide 
Disintegrant ** A or B 
Magnesium stearate 
Emcompress ad 
Tablet weight 200 mg 
**Disintegrant A is original Emcosoy 
Disintegrant B is modified Emcosoy 
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20.0% 
1.0% 
0.5% 
78.5% 
( 
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12. Tablet Production 
The active ingredient (or ingredients) was mixed with matrix 
in a twin shell dry blender for five minutes. The disintegrant 
was then added and mixing was continued for five minutes. After 
completion of this blending, stearic acid in Formulas I and II and 
magnesium stearate in Formula II was added, and the mixing process was 
continued for an additional five minutes. The formulations were 
compressed on a Stokes Rotary tablet press. A punch size of 3/8" 
for multivitamin and ascorbic acid formulations . and punch size of 
1/ 4 11 for pyridoxine formulations were used. 
Disintegrants were studied in the presence of single active .in-
gredient Formula II (pyridoxine hydrochloride) and Formula III 
(cscorbic acid), and more than one active ingredient (multi-vitamin 
formulation) Formula I, using water insoluble (Emcompress) and water 
soluble (Emdex) matrices. Tablets were made using various dis-
integrants with identical press settings ~ Formula I contained 
riboflavin, pyridoxine hydrochloride, niacin, and ascorbic acid 
as active ingredients. Emcosoy, Ac-Di-Sol, and Explotab were used 
as disintegrants at 0.5% and 1% level, and Emcosoy and corn starch 
at 3% level. Emcompress and Emdex were used as matrices. Stearic 
acid was used as lubricant at 2.5% level. 
Formula II contained Pyridoxine hydrochloride as active in-
gredient. Emcosoy , Ac-Di-Sol, and Explotab were used as disinte-
grant at 0.5%, 1%, and 2% level. Corn starch and Emcosoy were used 
( 
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as disintegrant at 2% and 3% level. Magnesium stearate was used 
as lubricant at 0.5% level. Emcompress and Emdex were used as 
matrices. 
Formula III contained ascorbic acid as active ingredient and 
stearic acid as lubricant at 2.5% level. Emcosoy, Ac-Di-Sol, and 
Explotab were used as disintegrant at 0.5%, 1%, and 2% level. Corn 
starch and Emcosoy were used at 3% level. At 2% disintegration 
level, granulated ascorbic acid was used, while the rest of the 
formulation contained ascorbic acid USP. 
Formulas I and III contained ascorbic acid as active ingre-
dient; stearic acid (2.5%) was used as a lubricant, since alkaline 
lubricant, such as magnesium and calcium stearate and minerals; e.g., 
talc and hydrated silica aluminate,were shown to decrease the 
stability of ascorbic acid tablets ( 66, 6 7). 
Physical Tests: 
Various physical tests were performed on the tablets: 
a. Weight: The weight of each individual tablet was deter-
mined by dusting each tablet off with a camel-hair brush, 
and placing it on an electric balance. This procedure was 
repeated for twenty tablets. The data from the tablets 
was analyzed for sample mean and Relative Standard De-
viation (R.S.D.), using a computer program. This pro-
cedure is explained below. The R.S.D . value was used as 
( 
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a measure of weight variation within a sample of tablets. 
The physical tests were run for twenty trials on each sample 
set. The data from the sample set was analyzed for mean 
value and Relative Standard Deviation (R.S.D.). A digital 
computer program written in Fortran was used to calculate 
these values, using the equation: 
Relative Standard Deviation = RSD 
Where: S is the Standard Deviation of Sample, and 
is the Sample Mean 
x 
The computer program used appears in Appendix 
b. Thickness: The thickness of twenty tablets was determined 
by first dusting off the surface of the tablet with a 
brush, and then placing it in the jaws of a micrometer. 
The measurements were recorded and analyzed for mean value 
and R.S.D. as a measure of variation. 
c. Hardness: The hardness of twenty tablets was determined by 
placing each tablet in an electronic hardness tester (Er-
weka) which recorded the breaking strength of the tablet 
in kilograms. This procedure was repeated twenty times, 
and the data were analyzed for sample mean and R.S.D. as a 
measure of variation. 
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( d. Friability: This test is a measure of abrasion resistance 
and was determined by first weighing twenty tablets after 
dusting, placing them in a Roche friabilator which rotated 
at a fixed rate for twenty minutes. The total weight of 
the twenty tablets (or what was left) was recorded, and 
the percent friability was determined as follows: 
Friability Weight (original) - Weight (Final) 100 1~~""'---~-'-~""'-~~~~--'~~_,__~--'-Weight (original) 
(17) 
e. Disintegration: Tablet disintegration was tested by using 
the U.S.P. apparatus wit~ discs as described in the Nation-
al Formulary XIV (68). Fig.3 schematically illustrates 
how this apparatus is set up. The time needed for all the 
fragments to pass through the mesh at the bottom of the test 
cage was noted visually, and was recorded. A mean value 
for six tablets was calculated, and the range of values was 
also recorded. 
f. Dissolution: Drug dissolution was measured using a U.S.P. 
apparatus, and according to monographs in U.S.P. XX. 
The exact equipment used was the U.S.P. "basket" assembly, 
and 5 ml samples were removed at times of 1, 2, 4, 7, 10, 
20, 40, 60,minutes, etc. until 100% dissolution was observed. 
Plots of these readings were made to depict the 
dissolution process. 
( 
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(2)-no disintegration, (1)-in process of disintegration, 
(3)-disintegration completed. 
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i. Dissograph: This is a programmable dissolution test 
apparatus. It has the capacity to monitor the dis-
solution of six tablets simultaneously. Sample solu-
tion was pumped from dissolution flask to a cuvette cell. 
Dilution was carried out if needed. Then samples were 
analyzed in a spectrophotometer. Readings were recorded 
on the Dissograph scale. The sampling time 
can be programmed according to convenience. The sig-
nificance of this apparatus is that all the functions 
are controlled automatically. The Dissograph was 
used to analyze the dissolution profiles of multi-
vitamin formulations. 
ii. Analytical Procedures: The dissolution medium was 
selected as appropriate for any given drug, on the 
basis of stability and solubility of drug. The drug 
or vitamin solution was scanned using 
an ultra-violet spectrophotometer to 
find Amax -- the wavelength at which the solution gives 
maximum absorbance. Once this value was determined, 
the spectrophotometer was set at this wavelength, and 
each sample was analyzed for absorbance at this wave-
length at various concentrations; the results were 
recorded in a Beer's plot. The drug monograph, as it 
appeared in the U.S.P. XX, was used as a reference for 
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determining the dissolution medium for the test. 
The dissolution samples (five milliliters) were not 
returned to the dissolution bath so that there was a cer-
tain amount of drug being lost in each sample. This drug 
loss was reflected in subsequent samples. This loss which 
must be accounted for was corrected by using a digital com-
puter program utilizing the following equations to deter-
mine the amount of drug in the five milliliter sample: 
Cone. = (A-b)/m 
Where: A is the absorbance 
m is the slope of Beer's plot 
b is the intercept of Beer's plot 
The computer program appears in Appendix 
(18) 
( 
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III. RESULTS AND DISCUSSIONS 
1. Scanning Electron Hicrographs: 
The scanning electron micrographs of Emcosoy are shown on pages 
51 and 52.As can be seen in figures4 , 5 the flake-like material appears 
to consist of the ground cell walls of soy beans and probably contains 
some proteinace.ous material. It swells in the presence of water, 
and the cellular nature of the soy polysaccharides appears to exert 
a wickirgeffect (20). This mechanisn of tablet disintegration is so 
effective that Emcosoy can be used as a tablet disintegrant in con-
centrations as low as .5%. 
2. Bulk Swelling and Water Uptake: 
Although investigators have proposed and evaluated numerous com-
pounds as tablet disintegrants, relatively few are in common use today; 
only modified starches, cellulose derivatives, and some ion-exchange 
resins are widely used. Depending on the type of disintegrant used, 
many theories relating to mechanism of action of tablet disintegration 
have been proposed, but none has fully explained the disintegrant pro-
perties of all the agents. Lowenthal, in two review articles, had dis-
cussed in detail the different mechanisms and factors affecting tablet 
disintegration (19.70)Xhe three major mechanisms of action are: (1) 
swelling, (2) porvisity and capillary action (wicking), and (3) de-
formation. Even though these concepts are listed separately, inter-
relationships probably occur in almost all tablet disintegration. 
so 
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SCANNING ELECTRON MICROGRAPHS OF EMCOSOY PARTICLES 
Fig 5 
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As explained in the experiment section, U-tube type apparatus was 
used for determining the bulk swelling of various disintegrants. Bulk 
swelling of Emcosoy, Ac-Di-Sol, CLD and corn starch were determined. 
All the disintegrants had equal initial volume in the calibrated tube, 
since the volume difference was used in calculating percentage swelling. 
For one disintegrant,different initial weight would give different 
percentages of swelling as found out in Ac-Di-Sol, Table IV, and graph 
on page 54. Logarithm of percentage swelling vs. time would give 
almost a straight line (Fig. 7 ). For different initial weight, the 
amount of water that would travel in a powder bed would vary (Fig. 8 ) . 
The amount of water travel would reduce as the weight of the disinte-
grant increased. 
The percentage of swelling decreased with increased initial weight 
of the disintegrant because the particles in the bottom portion of 
the tube came in contact with water of the reservoir first; they tried 
to swell, but their swelling was reduced by the weight of particles on 
the top. As the weight of the disintegrant was increasing, the bulk of 
particles on top was increasing; at the same time the amount of parti-
cles which were in contact with water remained the same. So, the swell-
ing was reduced with increases in weight of the disintegrant. 
Average bulk swelling of Emcosoy, Ac-Di-Sol, CLD, and corn starch 
were compared. Time required to reach the swelling and amount of 
water travelled in various disintegrantswere compared (Table I ) . As 
it can be seen from the table, Emcosoy had maximum swelling, while 
corn starh had no swelling. Time required to achieve that swelling 
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TABLE I 
Time Required to 
Reach Plateau 
10 min. 
90 min. 
20 min. 
6 min. 
TABLE LI! 
Disintegrant: Emcosoy 
Water Travelled 
in Powder Bed 
.3 ml. 
1.04 ml. 
.10 ml. 
.70 ml. 
Solvent: Citrate-Phosphate-Borate/Rel buffer 
PH % Swelling of Disintegrant 
2 00.00 
10.00 
4 14.29 
14.29 
6 28.S7 
lS.71 
8 22.86 
22.86 
TABLE III 
t Test for Buffer Reading 
Buff er PH S Computer t Table Value 
2 
4 l.8S 4.3 
2 
6 2.10 4.3 
2 
8 3.S7 4.3 
60 
% Swelling 
48.S7 
SS. 71 
8.96 
nil. 
Average Swelling 
S.00 
14.29 
22.14 
22.86 
Comment 
Not Significant 
Not Significant 
Not Significant 
( 
TABLE IV 
Disintegrant: Ac-Di-Sol 
Solvent: Distilled Water 
Weight of the Disintegrant (mg) 
250 
351 
425 
500 
750 
1000 
61 
% Swelling 
94. 29 
52.00 
20.00 
5. 71 
3 .00 
0. 77 
62 
TABLE V 
Disintegrant: Emcosoy 
( 
Solvent: Alcohol 
Solvent % Swelling Average % Swell 
0.0% alcohol 56 52 
48 
1.0% alcohol 43 43 
43 
4.0% alcohol 28 28 
28 
6.0% alcohol 30 29 
28 
15. 01~ alcohol 33 34.5 
36 
40.0% alcohol 23 23 
23 
95. 01~ alcohol 0.0 0.0 
0.0 
( 
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TABLE VI 
t-test for Alcohol Reading with Emcosoy as Disintegrant 
Alcohol % t Computed t Table Value 
0.0 
1.0 
0.0 
4.0 
0.0 
6.0 
0.0 
15.0 
0.0 
40.0 
0.0 
95.0 
2.25 
6.00 
5.58 
4.09 
7.25 
13.00 
Disintegrant: Emcosoy 
4.3 
4.3 
4.3 
4.3 
4.3 
4.3 
TABLE VII 
Solvent: Sodium Lauryl Sulfate (SLS) 
Solvent % Swell 
0.0% SLS 56 
48 
0.01% SLS 43 
38 
0 .10~~ SLS 44 
58 
5.40% SLS 14 
8 
Comment 
Not Significant 
Significant 
Significant 
Not Significant 
Significant 
Significant 
Average % Swell 
52 
40.5 
51 
11 
I 
64 
TABLE VIII 
( t Test for SLS Reading with Emcosoy as a Disintegrant 
SLS% t Computed t Table Value Connnent 
0 . 00 
0.01 2.44 4.3 Not Significant 
0.00 
0.10 0.12 4.3 Not Significant 
0.00 
5.40 8.2 4.3 Significant 
TABLE IX 
Disintegrant: Ac-Di-Sol 
Solvent: Citrate-Phosphate-Borate/Rel Buffer 
PH % Swelling of Disintegrant Average Swelling 
2 17.14 
21.43 19.29 
4 14.29 
10.00 12.15 
6 21.21 
15.71 18.46 
8 8.57 
17.14 12.86 
( 
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TABLE X 
t Test for Buffer Reading 
Buffer PH t Computed t Table Value Comment 
2 
4 2.35 4 . 3 Not Significant 
2 
6 .23 4.3 Not Significant 
2 
8 1. 34 4.3 Not Significant 
TABLE XI 
Disintegrant: Ac-Di-Sol 
Solvent: Sodium Lauryl Sulfate (SLS) 
Solvent % Swelling of Disintegrant Average Swelling ( 
00.00% SLS 5. 71 6.48 
7.24 
00.01% SLS 12.86 11.43 
10.00 
00.10% SLS 5. 71 7.14 
8.57 
05.40% SLS 0.00 0.00 
0.00 
10.00% SLS 0.00 0.00 
0.00 
65-a 
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TABLE XII 
t Test for SLS Reading 
SLS % t Computed t Table Value Comment 
( 
\ 0.00% 
0.01% 3.05 4.3 Not Significant 
0.00% 
0 .10% 0 .41 4.3 Not Significant 
0.00% 
05.40% 8.46 4.3 Significant 
\ 
,, 
( TABLE XIII 
Disintegrant: Ac-Di-Sol 
Solvent 
o;~ Alcohol 
1% Alcohol 
4% Alcohol 
6% Alcohol 
15% Alcohol 
40% Alcohol 
95% Alcohol 
t Test for Alcohol 
Alcohol % 
0% 
1% 
0% 
4% 
0% 
6% 
0% 
15% 
0% 
40% 
0% 
951~ 
% Swelling of Disintegrant 
Reading 
5. 71 
7.24 
11.43 
11.42 
7.14 
14.28 
8.57 
11.43 
14.29 
14.29 
14.29 
4.28 
7.14 
0.00 
0.00 
TABLE XIV 
t Computed 
6.47 
1.15 
3.93 
10.21 
0.47 
8.46 
t Table Value 
4.3 
4.3 
4.3 
4.3 
4.3 
4.3 
66 
Average Swelling 
6.48 
11.43 
10.00 
12.86 
14.29 
5. 71 
o.oo 
Comment 
Significant 
Not Significant 
Not Significant 
Significant 
Not Significant 
Significant 
( 
( 
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Swelling of Ac-Di-Sol in water , alcohol, and Sodium Lauryl Sulfate 
has been shown graphically ( Fig. · 9 to 11) . Emcosoy and Ac-Di-Sol 
swelling will not be affected significantly by the fluctuation of PH 
in the stomach, as well as the intestine. The most interesting ob-
servation was their swelling in Sodium Lauryl Sulfate solutions. As 
it appears in the table, Ac-Di-Sol particles had maximum swelling at 
.01% cone. of the solution, while no swelling was observed in 5.40% 
solution, which is recommended as a dissolution medium for drug-like 
Griseofulvin. The solution of Sodium Lauryl Sulfate at 5.40% cone. 
reduced the swelling of Emcosoy significantly. 
It was observed that very dilute alcohol solutions and Sodium 
Lauryl Sulfate solution reduced the surface tension of water, and 
they also acted as a wetting agent and enhanced the absorption of 
water by Ac-Di-Sol; but as their concentration increased, they ceased 
to act as wetting agents and there was relatively small proportions 
of water available for disintegrant to absorb. Therefore, swelling 
was reduced or, in some cases, swelling did not occur. 
3. Water Penetration of Disintegrations: 
Water penetration in Explotab, Emcos:oy, CLDII, and Ac-Di-Sol was 
measured. The square of penetrated length of powder bed versus time 
for various disintegrant was tabulted from Table 1..'V to XV iii. The same 
data was plotted on page 
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TABLE 1.'V 
( 
Disintegrant: Emcosoy 
2 
Time (sec.) Water Penetration in (cm) at 22 + le 
1500 1.02 
2400 1.86 
3600 2.82 
5160 4 .15 
6000 4.41 
TABLE XVI 
Disintegrant: Ac-Di-Sol 
2 
( Time (sec.) Water Penetration in (cm) 22 + le at 
1200 0.18 
2400 0.28 
3600 0.32 
6000 0.40 
TABLE XVII 
Disintegrant: CLD II 
2 
Time (sec.) Water Penetration in (cm) at 22 + le 
1200 0.18 
2400 0.28 
3600 0.45 
( 
4800 o. 71 
69 
( 
TABLE XVIII 
Disintegrant: Explotab 
Time (sec.) Water Penetration in (cm) 2 at 22 + le 
1500 3.57 
( 
2400 6.89 
3600 9.27 
4800 11.29 
6000 14. 29 
7200 16.60 
( 
-2 L 
18 
14 
10 
( c:n. 2) 
6 
2 
0 
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THE PENETRATION OF WATER INTO VARIOUS DISINTEGRANTS: 
Key 
0 Exp lot ab 
El Emcosoy 
A CLD II 
+ Ac-Di-Sol 
1800 3600 5400 72 00 
t (seconds) 
P..-lg. 12 
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is also very important, since in tablet disintegration it is expected 
( 
that disintegrant swells considerably to rupture the tablet as quickly 
as possible, so rate and extent of swelling are equally important. 
The penetrating rate of liquid into the disintegrant bed is ex-
press~ by Peek-McLean's equation ( 55 ) : 
dL ryCOS8 2 r dg 
dt 4NL Sn 
Where L is the penetrating length at time t, r is the average 
radius of void space, 8 the contact angle between liquid and powder 
surface, g the acceleration constant of gravity, and y, n, and d are 
the surface tension, viscosity, and specific gravity of liquids, res-
pectively. The penetration rate also depends on the viscosity of gel 
formed by the interaction of water and disingegrant. If the gel 
formed is too viscous, it would impede the further penetration of 
water in a disintegrant bed. All these factors will be discussed in 
great detail separately. 
In addition to water, water-alcohol mixtures of different strength, 
sodium lauryl sulfate solution of various concentrations and solutions 
of PH range 2 to 8 (Citrate - Phosphate - Borate/Rel buffer) were used 
to study the bulk swelling of Emcosoy and Ac-Di-Sol. Student t test 
was performed using Statpack computer program to find out whether the 
difference in swelling was significant or non-significant. All the 
readings and results are tabulated from Table IIto XIV. 
( 
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From the tables and graph, it appeared that water penetration rate 
was maximum in Explotab powder bed, followed by Emcosoy, CLD II, and 
Ac-Di-Sol under identical experiment conditions. The reason could be 
that average void space and contact angle between Explotab particle 
and water was high, compared to other disintegrants tested. 
4. Energy of Wetting: 
The values of K for different water temperatures for Emcosoy was 
tabulated in Table XIX. Log K/T vs.~ was plotted on page 73. The 
T 
value of ~ (the energy of wetting) was calculated for Emcosoy. 
I 
The value of energy of wetting obtained by this method according to 
some critics is an apparent value, since they believe that the approach 
is too simplified to give any real values. 
5. Wetting and Drying of Disintegrant: 
Emcosoy batches were prepared under different conditions. Bulk 
swelling was determined for these batches. Results are tabulated 
in Table XX. 
As it can be seen from the Emcosoy table that was dried at room 
temperature and at 40chad a bulk swelling less than the untreated 
(original) ·Emcosoy. One reason could be that these samples were dried 
at low temperatures, and therefore significant amountsof surface mois-
ture was left in these samples; that could have resulted in low water 
uptake and less swelling. 
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TABLE XIX 
Energy of wetting of Emcosoy particles 
Calculation 
k 
0.848 
1.955 
3.083 
0.4586 
0.8109 
0.9976 
x 10-3 
x io-3 
x lo-3 
From graph 
T 
295.0 
302.2 
310.0 
3.4 x 10-3 
3.3 x 10- 3 
3.2 x 10-3 
slope = - ~/R 
3 
-2.695 x 10= - p/1.987 Cai. 
~:;::; 5.35 K.cal. 
74 
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Emcosoy dried at 60 c had bulk swelling more than four times that 
of an original Emcosoy. The result could be explained by the comparison 
of baking of a cake with baking (drying) of a disintegrant particle. 
When the cake is baked, the surface area of the cake increases enor-
mously, and the same thing can happen in the disintegrant particles. 
The increase in surface area could lead to increased water uptake and 
increased swelling. 
Emcosoy dried at 60c had an improved flow and high density com-
pared to the original Emcosoy. The color change was from yellowish 
white to brown. No swelling was observed in the first two minutes 
in the original Emcosoy, but there was 30% to 35% swelling in the 
first two minutes in Emcosoy dried at 60 c. Wicking effect was very 
much improved in the Emcosoy dried at 60 c -- the time that was taken 
by the water to travel through the entire powder bed was 60 minutes, 
compared to 90 minutes for the original Emcosoy. 
There was little offending odor from Emcosoy dried at 40 c and 60 c, 
and visible mold growth in Emcosoy which was dried at room temperature. 
Published literature on the subject indicates that molds require a 
water activity number of 0.75, and bacteria requires 0.88. Below 
these values, microbial growth cannot be supported. It has been es-
timated that Emcosoy with a 10% moisture content = water activity 
number 0.5; and with 20% moisture content, there exists a water activity 
of 0.88. Since original Emcosoy usually contains less than 10% mois-
ture, it theoretically cannot promote microbial growth. However, in a 
76 
( wet granulation process, this argument might not betrue all the time. 
Prolonged storage or improper storage may lead to higher moisture 
content and consequently makes this disintegrant vulnerable to micro-
bial growth. 
c 
As discussed above, that Emcosoy dried at 60 had a better phy-
sical property than the original Emcosoy; they both were compared in 
actual tablet formulation. Original Emcosoy was identified as "A:' 
and the processed Emcosoy was identified as "B." In order to get un-
biased evaluations of these disintegrants, the tablets were prepared 
and tested by my colleague. The results and other details are shown 
in a tabular form (Table XXI) . 
As it can be seen from the table and contrary to expectation, pro-
cessed disintegrant tabletshad higher disintegrant time; in other 
words, the tablets made using it took a long time to disintegrate, 
compared to tablets made using original Emcosoy. The reason could be 
poor deformation of processed disintegrant. The three major mechanisms 
of disintegration are: (1) swelling, (2) porosity and capillary action 
(wicking), and (3) deformation. As mentioned above, processed disinte-
grant is better than original Emcosoy in the first two categories. 
There is no data to compare the third one. When the tablet is com-
pressed, the compression may cause more permanent deformation in ori-
ginal Emcosoy than the processed Emcosoy. When the tablet is put into 
a disintegrating medium, the energy-rich Emcosoy grains swell rapidly, 
unlike processed Emcosoy grains, which require more heat in order to 
swell. The overall effect leads to an early disintegration of the 
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TABLE XX 
Details % Swelling Average Swelling 
Emcosoy (original) 44.3 44.6 
(Passed through 100 mesh) 42 .9 
Emcosoy (dried at room temp.) 31.4 30.0 
2lc ( 28.6 
Emcosoy (dried at 40c) 34.3 32.15 
30.0 
Emcosoy (dried at 60c) 192. 7 197.1 
201.4 
( 
f ( 
\ 
( 
TABLE XX'l 
Hydrochlorothiazide 
Disintegrant ~ B f7 
Magnesium Stearate 
Emcompress 
Dis. Weight R.S.D. 
mg 
A 206.1 o. 779 
B 208.1 0.349 
,_, ;.. 
-· 
Thickness 
mm 
4.20 
4.21 
In Each 
Tablet 
40.0 mg 
2.0 mg 
1.0 mg 
157 .0 mg 
R.S.D. 
0.283 
0.225 
* Includes caps, without caps 12.68% 
**Includes caps, without caps 10.72% 
M = Mean 
R Range 
Percent 
20.0 
1.0 
0.5 
78.5 
Hardness R.S.D. 
Kg 
4.94 9 .162 
5.08 12.322 
78 
Working Formula 
60.0 Gm 
3.0 Gm 
1.5 Gm 
235.5 Gm 
Friab. Dis. Time 
% 
2.76* 6'40" M 
4'55"-11'10" R 
5'39" M 
3'45"-9'30" R 
2.63** 8 1 18" M 
4'40"-11'30" R 
8'48" M 
7'30"-12'35" R 
( 
( 
79 
tablet made from original Emcosoy. 
6. Aqueous Dispersion: 
Shangraw, et al, have theorized that substances that swell to very 
large gelatinous volume might be excellent disintegrants in a tablet 
that breaks apart rapidly; however, their inclusion in a tablet that 
disintegrates more slowly could lead to surface gelling that would only 
further impede liquid penetration of the tablet matrix ( 6 ). They 
compared two percent aqueous dispersions of various starches, cellulose 
products, and of cross-linked PVP in water-diluted hydrochloric acid, 
(1:100) were shaken periodically, and were allowed to stand overnight. 
They found that all the disintegrantshad different swelling; in some of 
the disintegrants, the swelling was enhanced or supressed in acidic 
medium. 
It is expected of ideal disintegrants that its swelling should 
remain unchanged or preferably increased in acidic medium, since most 
of the tablet disintegrates in acidic environments of the stomach. 
Emcosoy had 187.5 percent swelling in water, and 287.5 percent swelling 
in acidic medium. The results clearly indicated that vivo PH changes 
would have no adverse effect on disintegrating function of Emcosoy 
(Table XXIV). 
7. Comparative Study of the Viscosity of Different Strength Solutions 
of Various Disintegrants: 
Viscosity data of various disintegrant solutions are given from Tables 
XXII and XXIII. The disintegrants are divided into two groups: 
one under the heading, "Cellulose Group," and the other under the 
heading, "Starch Group." 
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TABLE XX.II 
Viscosity Study of Gel Formed by Various Disintegrants: 
Disintegrants rpm 2% 4% 6% 8% 10% 
Cellulose Group: 
Soy Cellulose 20 00.00 00.10 03.30 17.00 200.00 
(Emcosoy) so 00.08 00.14 02.60 16.00 120.00 
100 00.20 00.SO 01.69 14.00 88.00 
Cotton Cellulose 20 00.13 00.13 00.30 02.73 2S.60 
(Ac-Di-Sol) 50 00.22 00.3S 00.40 02.20 18.80 
100 00.22 00.40 00.7S 02.11 13.00 
Wood Cellulose 20 OS.90 224.00 1260.00 
(CLD II) so 04.68 146.90 664.00 
100 03.76 97.00 ------
Starch Group: 
Corn Starch 20 00.00 00.00 00.00 00.00 00.00 
50 00.04 00.10 00.08 00.08 00.12 
100 00.06 00.12 00.07 00.23 00.32 
Sta Rx lSOO 20 00.00 00.0S 00.00 00.00 00.12 
so 00.00 00.16 00.12 00.14 00.14 
100 00.00 00.18 00.36 OO.S7 00.21 
Sodium Starch 20 00.00 00.13 Ol.2S 148.SO S30.00 
Glycolate so 00.12 00.2S 01. 74 63.00 2S2.80 
(Explotab) 100 00.12 00.34 02.SS 39.20 136.80 
Polyplasdone XL 20 00.00 00.00 00.00 00.0S 00.4S 
(Grade c) so 00.00 00.00 00.06 00.10 00.42 
100 00.26 00.3S 00.4S 00.6S OO.S4 
TABLE XXIII 81 
Viscosity Study of Gel Formed by Various Disintegrants 
( Disintegrants rpm 12 /~ 14% 16% 
Cellulose Group : 
Soy Cellulose 20 464.00 
(Emcosoy) so 243.20 
100 1S6.00 
Cotton Cellulose 20 33S.OO 1310. 00 
(Ac-Di-Sol) so 196 .00 S94.40 
100 102.00 370.00 
Wood Cellulose 20 
(CLD II) so 
100 
Starch Group: 
Corn Starch 20 00.00 00.10 
so 00.08 00 . 10 
100 00.44 00.70 
Sta Rx lSOO 20 00.10 00.40 
so 00.30 00.SO 
100 00.36 00.64 
Sodium Starch 20 1980.00 
Glycolate so 
(Explotab) 100 
Polyplasdone XL 20 02.20 07 .OS 
(Grade c) so 01.66 04.36 
100 01.30 02. 70 
( 
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Cellulose Group: 
The viscosity of cellulose disintegrant solutions can be 
arranged in decending order: 
1. Viscosity of CLD II solutions, 
2. Viscosity of Emcosoy solutions, and 
3. Viscosity of Ac-Di-Sol solutions. 
CLD II solutions exhibited the maximum viscosity, compared 
to any disintegrant of either group. The gel formed by Ac-Di-Sol 
was less viscous compared to that of Emcosoy. If we have to 
justify the difference in the vitro bioavailability of two vitro 
formulations containing Emcosoy and Ac-Di-Sol, respectively, as 
disintegrants solely on the basis of viscosity, we can say that 
Ac-Di-Sol formulations will have a little superiority over Emcosoy 
formulations since the gel formed by Ac-Di-Sol will be less viscous 
than the gel formed by Emcosoy. As expected, cellulose derivatives 
form viscous gel compared to their starch counterparts. 
Starch Group: 
If the viscos~ty of starch disintegrant solutions has to be 
arranged in decending order, then: 
1. Viscosity of Explotab solutions, 
2. Viscosity of Sta-Rx 1500, and 
3. V~cosity of Corn Starch. 
Explotab gel has the maximum viscosity among starch disinte-
grants. If we have to predict the performance of Explotab and 
corn starch as disintegrant solely on the basis of the viscosities 
( 
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of their gel, we might expect corn starch as a better disinte-
grant than Explotab, since the gel formed by the former is less 
viscous. 
In practice, Explotab is much more superior to corn starch; 
the reason is that in addition to viscosity, there are other im-
portant factors, such as rate and extent of swelling, wicking 
effect, and deformation play crucial roles in disintegration 
mechanism. 
Explotab, Emcosoy, Ac-Di-Sol, and corn starch were compared in 
actual tablet formulations. The viscosity of the gel of Explotab 
is greater than that of Emcosoy. The viscosity of Emcosoy is greater 
than that of Ac-Di-Sol. Vitamin formulations studied clearly indicated 
that Explotab is inferior to Ac-Di-Sol and Emcosoy. Viscosity study 
provides the answer. Explotab swells much more compared to Ac-Di-Sol 
and Emcosoy, and we therefore expect it to be better disintegrant 
compared to Ac-Di-Sol and Emcosoy. However, that is not true, because 
Explotab forms very viscous gel, and it will be shown later that it 
has poor deformation. 
The disintegrant solutions were subjected to different shear rate, 
and the viscosity were determined. The rheological profiles of the 
various disintegrants were shown in Fig, 15 to 18 . In theory, there 
were all three kinds of profiles, as shown in Figure 14. In Newtonian 
liquids the viscosity remains unchanged with the increase in shear rate. 
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RHEOLOGICAL PROFILE OF POLIPLASDONE XL AT 14% CONC. OF THE 
DISINTEGRANT . 
Shear rate (rps) 
Fig. 1-7 
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In dilatant profiles, the viscosity increases with increases in shear 
rate. In pseudoplastic profiles, the viscosity decreases with in-
crease in shear rate. Emcosoy, Ac-Di-Sol, CLD II, Explotab, and poli-
plasdone XL gave pseudoplastic profiles. Corn starch and Sta Rx 1500 
solutions had dilatant profiles. Dilatancy could be one of the reasons 
for the poor vitro bioavailability of the formulations containing corn 
starch. 
· 8. Maximum Hydration Capacity of Various Disintegrants: 
Ac-Di-Sol -
Emcosoy -
CLD II -
16% W/V 
14% W/V 
8% W/V 
High hydration capacity is desirable property of disintegrant. 
High hydration capacity indicates that the disintegrant requires less 
amounts of water to wet itself thoroughly. It can be theorized that a 
disintegrant with high hydration capacity would relatively have smaller 
water uptake in order to achieve disintegration of the tablet, compared 
to a disintegrant with low hydration capacity. It can be said from the 
data that as the viscosity of the gel of disintegrant increases, the 
maximum hydration capacity decreases. 
9. Sieve Analysis: 
Nogami, et al, found that there should be the critical amount of 
starch necessary for the ~isintegration depending upon the particle size 
or specific area of ingredients. The smaller the particle size of as-
pirin, the more amount of starch was required for the tablet disinte-
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TABLE XXIV 
Emcosoy (2%) Dispersion in Water and Dilute Acid (Hcl 1 in 100) : 
Apparatus: 100 ml. measuring cylinder. 
Dilute Acid (1 in 100) Hcl. pH .70 
Time Duration: Overnight. 
Solvent Initial Volume End Volume 
Water 8.0 ml. 
Dilute Acid 8 .0 ml. 
Emcosoy - Sieve Analysis; 
Sieve Number U.S. Standard 
(Passed/Retained) 
100/170 
170/200 
200/230 
230/270 
270/325 
325/400 
400/Bottom 
d 
ave 
23.0 ml. 
31.0 ml. 
TABLE XXV' 
Arithmatic Hean 
Size of Opening 
5606 . 6 
90.6 
119 
81 
68 
58 
49 
41 
= 62 ~ 
~~ Swelling 
187.5 
287.5 
Wt. Retained 
on Smaller Sieve(%) 
8.5 
6.8 
11.4 
22.8 
32.7 
8.4 
4 .5 
Wt. 
Size 
1011. 5 
550.8 
775.2 
1322.4 
1602.3 
344.4 
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gration. The tablet of the smallest aspirin (11.9 in mean particle 
size) did not disintegrate by the addition of 20% of starch. Thus, 
the particle size of the ingredients play an important part in tablet 
disintegration (71). 
Rudnic, et al, studied the different particle size grades of cross-
linked polyvinylpolypyrrolidone (Polyplasdone,G.A.F. Corporation) in 
direct compression tablet for~_ulations showed tMt i1'l.<!!i'\'~a.ses in 
mean particle size enhanced powder flow, disintegration and dis-
solution, although hardness and friability were slightly better for 
tablets made from the finer grades ( 72). Therefore, particle size of 
the ingredients, as well as disintegrants, are equally important. 
There is nothing like optimum particle size of disintegrant or 
matrix. Particle size varies for various disintegrants and tablet 
matrices . However, the par ticle size should be such that disintegrant 
can be mixed and distributed uniformly with the rest of the ingredients. 
The particle size of Emcosoy was determined using sieving. Table XXV 
shows the size-weight distribution of Emcosoy as measured by U.S. 
Standard sieves. 
10. Plastic Deformation and Elasticity of Various Disintegrants: 
Modulus of elasticity at various attempted deformations and com-
pressive force needed to achieve that deformation were tabulated in 
Table X1.1!I.The percentage of plastic deformation and the percentage re-
( 
Disintegrant 
Emcosoy 
CLD II 
Ac-Di-Sol 
Exp lo tab 
Sta-Rx 1500 
Polyplasdone-XL 
TABLE XXVI 
Deformation 
Attempted 
10% 
20% 
40% 
10% 
20% 
40% 
50% 
20% 
10% 
20% 
20~~ 
10% 
20% 
40% 
Modules of 
Elasticity 
lb/in2 
328.35 
391. 4 7 
1063.95 
429.56 
570.45 
1677.85 
2013.42 
6291.95 
9357.93 
12931. 26 
5706.98 
377 .41 
503.35 
1142.79 
92 
Compressive 
Force (lbs) 
100 
175 
1240 
150 
340 
2000 
3000 
3750 
2850 
8050 
3250 
120 
300 
1400 
( 
Disintegrant 
Emcosoy 
CLD II 
Ac-Di-Sol 
Exp lo tab 
Sta-Rx 1500 
Polyplasdone-XL 
( 
TABLE XXVII 
Deformation 
Attempted 
10% 
20% 
10% 
20% 
10% 
20% 
10% 
10% 
20% 
10% 
20% 
I~ Plastic 
Deformation 
4.89 
13.33 
7.56 
13.33 
9.30 
12.44 
3.89 
8.0 
14.78 
6.22 
12.22 
93 
% Recovery 
5.11 
6.67 
2.44 
6 . 67 
0.70 
7.56 
6.11 
2.0 
5.22 
3.78 
7.78 
( 
( 
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covery of various disintegrants were tabulated in Table ~II. 
From the elasticity data, the disintegrants were arranged in the 
decending order of their elasticity on page 96. The order remained un-
changed for CLD II, polyplasdone-XL, and Emcosoy at 10%, 20%, and 40% 
attempted deformation. 
Force required to achieve various percentage of deformations for 
various disintegrants was tabulated on page 98. The force needed to 
attain 20% deformation in CLD II was little more than double of the 
force needed to attain 10% deformation in the same disintegrant. 
Similar observation was made in polyplasdone-XL, and to some extent 
in Emcosoy. However, when the deformation was doubled from 20% to 
40%, the force needed to achieve that deformation was almost five to 
six times than the force needed to achieve 20% of deformation. From 
these results, it was concluded that it was easy to deform particles 
initially; but as the percentages of deformation increased, the task 
became very difficult and greater force was needed to achieve those 
deformations. It was also observed that unusually high force was needed 
to achieve even 10% deformation in Explotab. It might be due to high 
degree of cross-linking among starch glycolate molecules. Cross-linked 
polymers of starch are more elastic, compared to their cellulose counter-
parts. At 20%, attempted deformation starch polymers required much 
more compressive force compared to cellulose polymers. 
( 
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The percentages of plastic deformation and the percentages of 
recovery at various attempted deformations for different disinte-
grants were tabulated on page 93. As it could be seen from the 
table, at 10% attempted deformation Ac-Di-Sol had more plastic 
deformation than Sta-Rx 1500 and CLD II, but at 20% attempted 
deformation order was reversed. It was clear from the data that the 
initial deformation might be more in Ac-Di-Sol compared to Sta-Rx 
1500 and CLD II, but the additional deformation -- the deforma-
tion after some initial range -- was less compared to Sta-Rx 1500 
and CLD II, which indicated that Ac-Di-Sol particles deformed 
initially easily but later they resisted more deformations. 
The recovery was least at 10% in Ac-Di-Sol, but at 20% the re-
covery was more than those of Emcosoy, CLD II , and Sta-Rx 1500. 
The disintegrants were arranged in decending order according 
to the plastic deformation (at 10% atteIT>ted deformation) on page 97 . 
The deformed particles are energy rich, and that energy is released when 
the grains are exposed to water. The energy-rich particles swell more 
rapidly in water, unlike undeformed grains, which require more heat 
in order to swell. These data provide an answer that why Ac-Di-Sol 
containing formulations had better disintegration and dissolution 
compared to formulations containing Emcosoy and Explotab. 
96 
ELASTICITY (decending order): 
( 
At 10% attempted defonnation: 
1. Exp lo tab 
2. CLD II 
3. Polyplasdone-XL 
4. Emcosoy 
At 20% attempted defonnation: 
1. Exp lo tab 
2. Ac-Di-Sol 
3. Sta-Rx 1500 
4. CLD II 
5. Polyplasdone-XL 
6. Emcosoy 
( At 40% attempted deformation: 
1. CLD II 
2. Polyplasdone-XL 
3. Emcosoy 
97 
( % PLASTIC DEFORMATION (decending order): 
at 10% at 20% 
1. Ac-Di-Sol 1. Sta-Rx 1500 
2. Sta-Rx 1500 2. CLD II, Emcosoy 
3. CLD II 3. Ac-Di-Sol 
4. Polyplasdone-XL 4. Polyp las done-XL 
5. Emcosoy 
6. Explotab 
RECOVERY (decending order): 
at 10% at 20% 
1. Exp lo tab 1. Polyplasdone-XL 
2. Emcosoy 2. Ac-Di-Sol 
3. Polyp las done-XL 3. Emcosoy, CLD II. 
4. CLD II 4. Sta-Rx 1500 
5. Sta-Rx 1500 
6. Ac-Di-Sol 
( 
( 
( 
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FORCE REQUIRED FOR 10% DEFORMATION OF VARIOUS DISINTEGRANTS: 
DISINTEGRANT COMPRESSIVE FORCE (lbs) 
Exp lo tab 2850 
CLD II 150 
Polyplasdone-XL 120 
Emcosoy 100 
--------------------------------------------------------------------
FORCE REQUIRED FOR 20 % DEFORMATION OF VARIOUS DISINTEGRANTS: 
DISINTEGRANT COMPRESSIVE FORCE (lbs) 
Explotab 8050 
Ac-Di-Sol 3750 
Sta-Rx 1500 3250 
CLD II 340 
Polyplasdone-XL 300 
Emcosoy 175 
FORCE REQUIRED FOR 40 % DEFORMATION OF VARIOUS DISINTEGRANTS: 
DISINTEGRANT 
CLD II 
polyplasdone-XL 
Emcosoy 
COMPRESSIVE FORCE (lbs) 
2000 
1400 
1240 
( 
( 
( 
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11. TABLET PRODUCTION: 
Tables XXVIII through XXXII show physical properties of the tablet 
formulae I, II, and III. 
High weight variation, thickness and high hardness variation 
were observed in multivitamin formulation (Formula I). Capping 
was observed in a formulation having Emcompress as a matrix. Em-
dex matrix formulation ~ave friability less than .90%. Disinte-
gration time was less than 20 minutes in most of the formulation 
Pxcept formulation containing corn starch at 3% level in Emcompress matrix. 
It is obvious from the disintegration time in Tables XXVIII and XXIX that 
the effect of various disintegrant is much pronounced in water-in-
soluble matrix, such as Emcompress, compared to water-soluble matrix, 
such as Emdex. Dissograph was used for the dissolution study. Total 
optical absorbance was measured. From each formulation three dis-
solution profiles were studied. The results were quite reproducible (Tables 
XX.XIII qnd XX.XIV). Emdex matrix gave t 50 , t 75 , and t 90 within a range 
of two to nine minutes for various disintegrants at various concentra-
tion; while in the case of Emcompress matrix, those values differed 
considerably. Corn starch at 3% level gave t 75 and t 90 more than 
30 minutes. Corn starch and Emcosoy was compared at 3% level in Em-
compress as a matrix. Obviously, Emcosoy was a better disintegrant 
than corn starch (Fig.z7). 
( 
100 
A narrow weight variation, hardness variation, and thickness 
variation were observed in pyridoxine HCl formulation (Formula II). 
Hardness was optimum. Tablets with Emdex as a matrix were thicker 
than Emcompress matrix tablet. Capping was a problem in some of the 
formulation containing Emcompress as a matrix. The friability was 
less than .50% in Emdex matrix formulations. As observed in multi-
vitamin formulation, the effect of various disintegrants at different 
concentration was more pronounced in Emcompress matrix compared to 
Emdex matrix formulation. At .5% disintegrant level the tablet con-
taining Explotabs disintegrant and Emcompress as matrix failed to 
disintegrate within one hour, although at 1% and 2% the same dis-
integrant was found satisfactory. At 2% disintegrant level, all the 
disintegrants except corn starch were found satisfactory. Tablet 
containing corn starch as disintegrant at 2% level failed to dis-
integrant within one hour. All formulations containing Emdex as a 
matrix gave disintegration time less than at eight minutes at various 
disintegrant levels. Two dissolution profiles were studied from each 
formulation. At 0.5% disintegration level in Erncompress matrix Em-
dosoy, Ac-Di-Sol and Explotab had t 90 more than 30 minutes; at 1% 
and 2% disintegrant level t 50 , t 75 , and t 90 was found satisfactory 
for these three disintegrants. However, at 2% level corn starch gave 
t 90 more than 30 minutes compared to t 90
1 s of Emcosoy 1.5 minutes, 
Ac-Di-Sol three minutes, and Explotab 9.5 minutes (Fig.49). In Emdex 
( 
( 
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matrix all disintegrants gave satisfactory t 50 , t 75 , and t 90 . However, 
it was obvious from Tables XXXV and XXXVI that Emcosoy was superior to corn 
starch in both matrixes, and it competed successfully with Explotab 
and Ac-Di-Sol. 
High weight, thickness and hardness variation were found in As-
corbic acid formulations (Formula III, Table XXXII). Ascorbic acid for-
mulations contained only Emcompress matrix. Hardness was little less 
than optimum when applied pressure. Hardness increased first, and 
then decreased. Capping was found at low concentration level of dis-
integrant. Ascorbic acid is highly water soluble compared to other 
active ingredients used, so the disintegration time was much less ex-
cept when corn starch was used as disintegrant. All formulations at 
2% disintegrant level contained granulated Ascorbic acid (90%) (Roche); 
the rest of the formulation contained Ascorbic acid U.S.P. Granulated 
Ascorbic acid was less soluble compared to Ascorbic acid U.S . P.; hence, 
little high disintegration time was observed at 2% compared to 1% and 
.5% disintegrant level. Two dissolution profiles were studied from 
each formulation. The results were generally reproducible (Table :XXXVII) 
tso• t 75 , and t 90 were satisfactory except for corn starch formulations. 
Corn starch at 2% and 3% gave t 75 and t 90 more than 30 minutes. It 
was very interesting to compare corn starch and Emcosoy at 3% level 
(Fig. 80), since both were all natural disintegrants: t 90 for Emcosoy 
was two minutes, while for corn starch it was more than 30 minutes. 
N TABLE XXVI I I 0 
rl MULTIVITAMIN FORMULATIONS WITH EMCOMPRESS AS A MATRIX 
WEIGHT THICKNESS HARDNESS FRIABll.ITY DISINTEGflATION TUIE 
mg mm Kg Percent min-sec 
Mean Range 
0 . 5% Disintegrant 
Emcosoy 366.0 (I. 21) J.78 (0.98) J.75 (57.JO) CAP* IO.IO 5.40 to 19.15 
Ac-Di-Sol 376.0 (1.511) J. 8l1 (l. 31) 3.52 (48.84) CAP 4.13 3.10 to lo . 35 
Explotab 354 . 7 ( 1. 62) 3.84 ( 1. 19) 3.83 (17.83) 3. Ito 12.11 IO.OJ to 16.50 
1.0% Disintegrant 
Emcosoy 358.0 (1. 23) 3.76 (0.66) 11.30 (43.26) CAP J . 19 2.0 to 4.10 
Ac-Di-Sol 373.6 (0.81) 3.83 (0.92) 3.66 (39 . 92) CAP 1.56 1.10 to 2.25 
Exp lot ab 364.3 (0.55) 3.74 (0. 73) 7.08 (32. 51) CAP 4 . 29 3.20 to 5.10 
3.0% Disintegrant 
Emcosoy 356.1 (1. 29) 3. 77 (O. 71) 4.73 (38 . 41) CAP 1.15 0.50 to 1.50 
Corn Starch 379.5 (1.13) 3.88 (1. 03) 4.51 (26.62) CAP 37.31 34.00 to 40.10 
*Capping 
NOTE: In this and all subsequent tables, values in parentheses are Relative Standard Deviation. 
~ 
.__., 
("') 
0 
r-1 
'---" 
O. S% Disintegrant 
Emcosoy 
Ac-' Di-Sol 
Explotab 
1.0% Disintegrant 
Emcosoy 
Ac-Di-Sol 
Explotab 
3 .0% Disintegrant 
Emcosoy 
Corn starch 
WEIGHT 
mg 
346.2 
3S7 . S 
3SS.8 
3S3. l· 
362. l 
372.S 
342.7 
412.4 
TABLE XXIX 
MULTIVITAMIN FORMULATIONS WITH Et-IDEX AS A MATRIX 
THICKNESS HARDNESS FRIABILITY DISINTEGRATION TIME 
mm Kg Percent min-sec 
Mean Range 
(O. 73) 4.42 (0.70) ll.S3 (7 . 78) O.Sl 3.SO 3 . .JO to l1 .OS 
( l. 29) 4.46 (0.89) 11.37 (9.S8) 0.62 3.13 2 .SO to 3. 20 
( 1.60) 4.47 (l.08) 10.37 (7 .SI) o.ss 3.19 3. IS to 3. 20 
( l. 33) 4.36 (0.98) 9 .60 (16 .60) o. 73 3.2S 3.20 to 3.40 
(1.18) 4.40 (0.94) 11.26 (13.17) 0.80 4.08 3.SO to 4.20 
( 1. 68) 4. S8 ( 1. 39) 10.6S (10.64) o. 73 4.06 3.40 to 4.20 
( 1.13) 4.48 (0.90) 9.33 (14.03) O.S9 4 .18 4.00 to 4.40 
(2.0S) S.13 (S.74) 11.51 (14.58) 0 . 64 5.05 4.40 to 5.10 
....._, 
-::t 
0 
rl 
"---" 
FOfilRJLATIONS 
O.Sr, Disintegrant 
Emcosoy 
Explotab 
Ac-Di-Sol 
1.0% Dlsintegrant 
Emcosoy 
Exp lo tab 
Ac-Di-Sol 
2.0% Dlalntegrant 
Explotab 
Ac-Di-Sol 
Emcosoy 
Corn Starch 
*CAP - CAPPING 
TABLE XX.X 
PYRIDOXINE HCL FOR~RJLATIONS wrm EHCOMPRESS AS A MATRIX 
WEIGHT 1111CKNESS HARDNESS FRIAllILlTY 
mg mm Kg Percent 
209.0 (0.44) 4.23 (2.35) 8.81 (20.41) 0.81 
216. 7 (0.30) 4.12 (O.Sl) 8.04 (38 . 83) CAP* 
211.6 (O.SO) 4.43 (3.38) 9.91 (l0.26) 0.63 
205.8 (0.61) 4.08 (3.88) 7.30 (lS.74) 0.65 
-
210.6 (0.41) 4.Sl (5.74) 7.21 (19.48) CAP 
212. 1 ( 1. 29) 4.13 (0.43) 7 .36 (25.49) CAP 
211.0 (0.511) 4.69 (4.49) 7.92 (17.03) CAP 
205.3 (0.117) 3.95 (J.01) 6.45 (23.40) CAP 
208.S (0.76) 4.13 (0.39) 8.H (lS.16) 0. 31, 
218.S (0.82) /1.12 (0.65) 10.93 (18.04) l.49 
~ 
DlSINTEGRATION TIME 
min. sec. 
mean range 
23. lS 16.30-35.00 
More than l hour 
S.02 l, .110- s. 25 
2.36 2.20- 2.45 
23.05 11.20-32.10 
4.17 3.25- 4.30 
4.10 3.10- 4.30 
1.01 0.45 - 1.20 
1.0 .50- 1.1s 
-
more than 1 hr 
Lr) TABLF. XXXI 0 
~ 
PYRIDOXINE llCL FORMULATION WITH EMDEX AS A MATRIX 
WEIGHT THICKNESS HARDNESS FRIABILITY DISINTEGRATION TIME 
mg mm Kg Percent ifin-sec me 1 range 
-
0.5% Disintegrant 
Emcosoy 202.3 (0.60) 5.36 (0. 31) 12.47 (11.73) o. 29 5.10 4.50 to 5.30 
Ac-Di-Sol 207 .8 (0.50) 5.37 (0.37} 13. 38 (11. 61) 0.39 3.51 3 . l10 to 4 . 00 
EY.plotab 205.9 (0.44) 5.3l1 (0. 31) 12.44 (14 .33) 0 . 35 5.09 4.40 to 6.00 
l.0% Disintegrant 
Emcosoy 209 . 3 ( 0 • 4 7) 5.37 (0.40) 13.05 (ll.47) 0.29 4.02 3.50 to 4.10 
Ac-Di-Sol 213.3 (0.80) 5.39 (0.53) 12.58 (12.66) 0.115 4.05 3.50 to 4.30 
Explotab 212.9 (0.52) 5.65 (2.82) 12.41 (10.02) 0.38 4 . 11 3.20 to 4.30 
3.0% DisinteB!.ilnt 
Emcosoy 214.5 (0.47) 5.61 (0. 75) 10.88 (12.91) 0.44 3.00 2.80 to 3.20 
Corn starch 226. l (O. 79) 5. 73 (0.40) 13 . 37 (12.19) 0.33 6.00 5.10 to 7.25 
....._, 
'--
TABLE XXXII 
\ 0 
0 ,.., ASCORBIC ACID FORMULATION WITII EMCOMPRESS AS A MATRIX 
WEIGHT TUICKNESS HARDNESS FRIABILITY DISINTEGRATION TIME 
Kg Percent mins.-sec mg nun mean range 
9.sx Disintegrant 
Emcosoy 397.9 (0.88) 4.05 (0.80) 3. so ( 60. 29) CAP* l.15 0.58 to 1.30 
Ac-Di-Sol 402.2 (l.36) 4 . 07 (l.26) 3 . 35 (67 . 07) CAP 0.56 0.40 to l.20 
1.07. Disintegrant 
Emcosoy 399.9 (5.47) 40.60(2.16) 4.81 (34.74) CAP 0.51 0. 25 to l. 25 
Ac-Di-Sol 466.1 (4.67) '~.39 (3 . 24) 3.00 (53.32) CAP 0.31 0. 20 to 0.40 
Exp lo tab 377.4 (1.97) 3 . 90 (l.44) 4.61 (15.17) 2.05 2.21 1.20 to 3.25 
2 . 0% Disintegrant 
Emcosoy 378·0(1. 92) l1 .08 (1.06) 4.25 (19.92) 1. 74 0.116 0.40 to 0.55 
Ac-Di-Sol 388·0(0. 96) 4.13 (0.85) 11.9 (13.48) 1. 67 0.46 0.40 to 0.55 
Exp lo tab 395.3 (0!79) l1. 18 (O. 83) 5.32 (15 . 46) 1. 4'1 2.57 2.20 to 3.20 
Corn Starch 1108.3 (0.94) 4.20 (0.63) 5.9 (18.66) 1. 67 22.18 18.10 to 24.30 
3.07. Disintegrant 
Emcosoy 393 (3.30) 4.07 (2.24) 5.37(33.30) 1. 39 0.30 0.25 to 0.40 
Corn Starch 440.2 (1.58) 4. 34 ( 1.13) 2.11 (84.24) CAP 14 .10 12.30 to 15.00 
*CAPPING 
"-----' 
~ 
( 
Dissolution data: 
Formulation 
Emcosoy 
Ac-Di-Sol 
E.xplotab 
( Emcosoy 
Ac-Di-Sol 
Exp lo tab 
Emcosoy 
Corn starch 
'.LABLE XXXIII 
Formulation: Riboflavin 0.57% 
Pyridoxine Hcl 0.86% 
Niacin 5 .70% 
Ascorbic acid 17 .1 0% 
Disintegrant 0.5% or 1.0% or 3.0% 
Stearic acid 2 . 5% 
Emcompress ad 100% 
t 50 (min) 
8.45 
8. 75 
10.10 
J.70 
3.80 
4 . 20 
10 .10 
10 . 25 
11.50 
2 . 60 
6.20 
9.30 
1.50 
1.90 
1.90 
5 . 10 
5 . 20 
6. 75 
1.55 
2.00 
18.25 
20.55 
t 75 Cmin) 
11. 75 
12 . 40 
12.80 
4.80 
5 . 00 
5.30 
15 .10 
16.30 
17.30 
4.10 
8.30 
13 . 95 
2 . 60 
2.75 
3. 10 
6 .25 
7.20 
8.00 
2.95 
2.95 
7 30.00 
"7 30.00 
107 
t 90 (min) 
14.00 
14.60 
14. 75 
6 . 75 
7.65 
8.40 
17 .40 
18 . 30 
20.20 
6 . 80 
10 . 55 
16.90 
3 . 60 
3.60 
5.20 
7 . 15 
8 . 90 
10.80 
3.60 
3.60 
> 30.00 
> 30.00 
( 
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Formulation: 
Key: 
Riboflavin 0.57% 
Pyridoxine Hcl 0.86% 
Niacin 5.70% 
Ascorbic acid 17.10% 
Disintegrant 
Stearic acid 
Emcompress ad 
0.5% 
2.5% 
100% 
e Emcosoy 
.il Ac-Di-Sol 
• Explotab 
20 
Time in minutes. 
Fig. 19 
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I ' 10 20 30 
Time in minutes. \ 
Dissolution profile of multi vitamin formulation containing 0.5% of Emcosoy 
Replicate l • ,Replicate 2 e ,Replicate 3 (J • Emcompress as a matrix. 
Fig. 20 
( 
..; 
Ill 
> 
..... 
0 
"' 
"' ..... ( Q 
... 
~ 
(.J 
... 
Ill 
"" 
100 
90 
llO 
a. 
4 
10 20 30 
Time in lldnutes. 
Dissolution profile of multi vitalldn formulation containing 0.5% of Ac-Di-SOl 
Replicate 1 A ,Replicate 2 A ,Replicate 3 A Emcompress as a matrix. 
Fig . 21 
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Dissolution profile of llllllti vitamin formulation containing O.Si. of Explotab 
Replicate 1 .,Replicate 2(3 ,Replicate 3 () Emcompress as a matrix. 
Fig. 22 
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Formulation: 
Key: 
Riboflavin0.577. 
Pyridoxine Hcl 0.867. 
Niacin 5 . 707. 
Ascorbic acid 17.10% 
Disintegrant 1.0% 
Stearic acid 2.5% 
Emcompress ad 100% 
• Emcosoy 
A Ac-Di-Sol 
• Explotab 
20 
Time in minutes. 
Fig. 2.3 
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Dissolution profile of multi vitamin formulation containing 1% of Emcosoy 
Replicate 1 e ,Replicate 2<!) ,Replicate 3 <I , Emcmpress as a matrix. 
Fig. 24 
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Dissolution profile of multi vitamin formulation containing 17. of Ac-Di-Sol 
Replicate 1 A, Replicate 2~ ,Replicate 3 4 Emcompress as a matrix. 
Fig. 25 
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Dissolution profile of multi vitamin formulation containing 1% of Explotab 
Replicate l D Replicate 2 a ' Replicate 3 • ' Emcompress as matrix. 
Fig. 26 
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Formulation: 
Riboflavin 0.57% 
Pyridoxine Rel 0.86% 
Niacin 5.70% 
Ascorbic acid 17.10% 
Disintegrant 3.0% 
stearic acid 2.5% 
Emcompress ad 100% 
4t Corn starch. 
20 
Time in minutes. 
Fig. 27 
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Dissolution profile of multi vitamin formulation containing 3% of Emcosoy 
Replicate 1 $ Replicate 2 e Emcompress as a matrix. 
Fig. 28 
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Dissolution ~rofile of ~ulti vitamin formulation containing 3% of Corn starch 
Replicate 1°© Replicate 2 • Emcompress as a matrix. 
Fig. 
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Formulation: Riboflavin 
Pyridoxine Hcl 
Niacin 
Ascorbic acid 
Disintegrant 
Stearic: acid 
Emdex ad 
Dissolution data: 
Formulation 
Ecncosoy 
Ac-Di-Sol 
Explotab 
E.mcosoy 
Ac-Di-Sol 
faplotab 
Emcosoy 
Corn starch 
TABLE XXXIV 
0 . 57% 
0.86% 
5. 70% 
17.10% 
0.5% or 
2 . 5r, 
100% 
2. 95 
2.95 
3. 20 
3. 00 
2.60 
2.40 
2.40 
2.65 
2 .85 
2.80 
3. 15 
3. 25 
2.45 
2.55 
2 . 75 
3. 55 
3.60 
3.60 
2 .75 
2.75 
3.20 
3.75 
l.0% or 3.0% 
119 
t75(min) 
3.55 4 . 75 
3.55 4.75 
3.75 4.75 
4.80 6.65 
4.20 6.00 
3.90 5.30 
3.60 6.00 
4.00 5.70 
4 . 20 5.JO 
5.20 6 . 75 
5 . 40 5.20 
5. 40 6.75 
3.75 5. 20 
3. 75 5 . 20 
4.25 6 .10 
4.20 6. 45 
4.60 6.65 
~.60 6.65 
3 . 85 5 . 20 
4 . 05 5. 40 
5.60 8 . 00 
6.50 8.90 
Dissolution profiles. 
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Formulation: 
Key: 
Riboflavin 
Pyridoxine Hcl 
Niacin 
Ascorbic acid 
Disintegrant 
Stearic acid 
Emdex ad 
e Emcosoy 
.t. Ac-Di-Sol 
• Explotab 
10 20 
Time in minutes. 
Fig. 30 
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Dissolution profiles of multi vitamin formulation containing0.5% of Emcosoy 
Replicate l ~ ,Replicate 2 €) , Replicate 3 ~ Emdex as a matrix. 
Fig. 31 
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Dissolution profile of 0.5% of Ac-Di-Sol in multi vitam.i~ formulation 
Replicate 1 • ,Replicate 2 (I Replicate 3 CE Emdex as a matrix. 
Fig. 32 
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Dissolution profiles of multi vitamin formulation containing O.Si. of 
Explotab. Replicate 1 ~ , Replicate 2 4 , Replicate 3 ~ Emdex as a matrix. 
Fig. 33 
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Formulation: 
Key: 
Riboflavin 0.57i. 
Pyridoxine Hcl0.86i. 
Niacin 5.70% 
Ascorbic acid 17.lOi. 
Disintegrant 1.0i. 
Stearic acid 2.Si. 
Emdex ad 100% 
e Emcosoy 
A Ac-Di-Sol 
8 Explotab 
20 
Time in minutes. 
Fig. 34 
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Dissolution profile of multi vitamin formulation containing 1% of Emcosoy 
Replicate 1 e , Replicate 2 O ,Replicate 3 () Emdex as a matrix. 
Fig. 35 
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Dissolution profile of multi vitamin formulation containing li. of Ac-Di-Sol 
Replicate 1 A , Replicate 2 A , Replicate 3 4 Emdex as a matrix. 
Fig. 36 
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Dissolution profiles of multi vitamin formulation containing 1% of Explotab 
Replicate l • , Replicate 2 IE , Replicate 3 (] Emdex as a matrix. 
Fig. 37 
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Formulation: 
Key: 
Riboflavin 
Pyridoxine Hcl 
Niacin 
Ascorbic acid 
Disintegrant 
Stearic acid 
Emdex ad 
e Emcosoy 
• Corn starch 
20 
Time in minutes. 
Fig. 38 
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Dissolution profiles of multi vitamin formulation containing 3% of ~Emcosoy 
Replicate 1. , Replicate 2 0 Emdex as a matrix. 
Fig. 39 
( 
.,, 
OJ 
> 
..... 
0 
"' 
"' .....
0 
100 
90 
130 
Time in minutes. 
Dissolution profiles of multi vitamin formulation containing 3% of Corn starch 
Replicate 1 © ,Replicate 2 • Emdex as a matrix . 
Fig. 40 
( TABLE XXZV 
Fenn.la II: Pyricic-:r.foe P.c 1 5:1. 
Formulation 
0.5% Disinte!Eant 
Emcosoy 
Exp lo tab 
Ac-Di-Sol 
LO % Disintegrant 
Emcosoy 
Exp lo tab 
Ac-Di-Sol 
2.0% Disinte!!jrant 
Exp lo tab 
Ac-Di-Sol 
Emcosoy 
Corn starch 
Djs i ntegrant 0 .5 % er 1.0% er 2.0% 
~~g. Ste£rate C. 5% 
Emc.c·mpr&E.s <.=ci 1007: 
t 50 Cmin) t 75 (min) 
12.2 22.2 
16.0 >30.0 
14 .1 >30.0 
19 . 9 >30.0 
2.7 9.5 
3. 8 15.8 
1.8 3.8 
4.8 10.5 
3. 7 14.0 
6.2 15 .o 
2,0 5.1 
;; .9 6.8 
0.9 3.8 
1.6 4.3 
0.8 J.2 
C· . 8 1.2 
0.5 0.8 
0 . 5 1. 0 
16.0 27 . 0 
25.0 >30.0 
131 
t 90 Cmin) 
29.l 
> 30.0 
> 30.0 
> 30.0 
18.4 
> 30.0 
6.5 
18.2 
approx 30.0 
approx 30.0 
13.1 
15.2 
9 . 5 
9.5 
2 .0 
- 3.0 
1.0 
1. 5 
> 30.0 
>30.0 
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TABLE 2'..XXVI 
Formulation: 5% Pyridoxine Hcl 
Disintegrant 
Mag. Stearate 
Emdex ad 
0.5% or 1.0% or 3.0% 
0.5% 
100% 
DISSOLUTION DATA: 
------------------
Formulation 
t50(min) 
0.5% Disintegrant 
Emcosoy 4.35 9.60 
4.42 9. 75 
Ac-Di-Sol 3 . 40 9 .20 
4.05 9.70 
Exp lo tab 4.20 11.60 
5 . 30 15.60 
1.0% Disintegrant 
Emcosoy 5.10 10.40 
5 .15 12.30 
Ac-Di-Sol 4.60 10.50 
6.70 16.85 
Explotab 2.35 8.10 
4.60 13.15 
3.0% Disinte5rant 
Emcosoy 3.20 7.40 
Corn starch 6.50 17.85 
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15 .10 
17.45 
14.70 
16.30 
21.20 
26.80 
15. 70 
19.15 
16.90 
730.00 
14.30 
16.60 
12.65 
27.25 
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TABLE D"~CVII 
Formulation: Ascorbic acid 25% 
Disincegrant 0.5%,1%,2%or 3% 
scearic acid 2.5% 
Emcompress ad 100% 
DISSOLUTION DJ.TA : 
Formulation t5o (min) t75(min) 
0.5% Disintegrent 
Emcosoy 2.20 3.20 
2;50 : . . 70 
Ac-Di-Sol 1.20 1.60 
1. 35 1.95 
1.0% Disintegrant 
Emcosoy 0.60 0.84 
l.05 1.50 
Ac-Di-Sol 0.85 1.30 
0.85 1.30 
Exp lo tab 2 . 25 4.80 
2.45 5 .10 
2.0% Disintegrant 
* Emcosoy 1.30 ... oo 
1.20 1.40 
Ac-Di-Sol 1.50 2.55 
1.80 2.40 
Ex~lotab 4 . 35 6.60 
6.00 8.30 
Corn Starch 23.10 ;no.oo 
30.00 )' 30.00 
3.0% Disintegrant 
Emcosoy 0.45 0.90 
0.80 l..+O 
Corn starch 17.60 /'30.00 
18.40 730.00 
~ Granulated Ascorbic acid(90%) (Roche) was used at 2.0% 
level,re£t fc rmulatior,s cc.ntaine:d A:.cortic ac:!.d l!.S.P. 
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t90 (min) 
L.05 
5.60 
2 . 40 
2.55 
1.80 
1.80 
2 . 20 
2.20 
5.75 
6 .15 
3.20 
2.00 
4.00 
2.80 
7.85 
9.60 
7 30.00 
7 30 .00 
1.05 
2.00 
7 30.00 
/'30.00 
disintegrant 
( 
Dissolution profile2 
JOO 
90 
""' 50 
" > 
~ 
<:. 
en 
en 
.,., 
::.J 
... 
i..; 
" u 
.... 
<lJ 
""' 
10 
TilllE: in rri.ni.tei:. 
Fig. 64 
Forn•ulatior : 
Ascc·rbj_c o.c:i.ci 25% 
Ofaj_ntEgrant 0 .S i; 
Ste&ric o.cid 2.5% 
Emcc-o~· ress: .:<l lOO i. 
Ke.y: 
A Ac-·Di-Sol 
e Emcc·sc:y 
::o 
157 
158 
( 
100 
90 
'\J 
"' :>
~ 
Q 
"' 50 
"' .,., 
""' 
... 
= 
"' u
... 
~ 
• 
10 30 
Time in m.:i.nutes. 
Dissolution ~re files fc.r AE'.c.crbic z.cid f c rl!!ulati or:s cc·ntaj ning C. 5% Emcc.:sc.y 
RE:plico:te 148 ,Replicc;te 2 e 
Fig. 65 
( 
100 
S·O 
'O 
"' ;> 
..... 
u 
v, 
"' 
.,., 
~ 
.... 
.:o 
,;;.: 
"' t 
~ 
""' 
159 
20 :.o 
Time in m:i.nutes. 
Dissolutior. profiles fer A.c:cc•rbic acid formularior.s cootaj.njng 0.5% Ac.-·Di-~c; l 
Rq:J.jcr.te 1 A ,Rq:liczte. 2 • 
Fig. 66 
( 
( 
"' OJ > 
...... 
0 
"' 
"' .....
<=l 
Dissolution profiles. 
100 
.90 
10 
Formulation: 
20 
Time in minutes. 
Fig . 67 
Ascorbic acid 25% 
Disintegrant 1.0% 
Stearic acid 2 . 5% 
Smcompress ad 100% 
Key: 
e Emcosov 
A Ac-Di-Sol 
• Explot:ab 
160 
( 
JOO 
so 
.,,; 
"' ,. 
..... 
0 
"' 
"' 
'-l 
.... 
SG 
i;;.; 
"' v 
... 
"' .....
10 ;.o 
Time in rrd.nute.s. 
161 
30 
Dissolution profjlEi'E for Ascorb'ic acid fornn.11.at:ionE ccrtaini.ng 1% Emc:csoy 
Repl icz.t:e I CD , Re:plicc..te 2 e 
Fig. 68 
162 
( 
100 
90 
"O 
jJ 
> 
~ 
v 
uJ :o 
"' ~ 
...... 
.... 
.,;.:,; 
w 
v 
;... 
<IJ 
~ 
10 20 
Time Jn minutes. 
Dissolution i·rofilee c.ontalnjrig 1% Ac-·Di-Sol in Ascc·rl:ic o:cid formulation:: 
P.e.pl.Jcate l &. , Re,plic<.te 2 A 
Fig. 69 
( 
100 
90 
'\J 
"' > 
..... 
Q 
"' 
"' 
SG 
.... 
Q 
..... 
.:; 
"' u
~ 
il: 
• D 
10 20 
Time in ~inutes. 
30 
163 
Disscltition profiles fer Ae;cc·rb i c o:c.id formulation containin~ 17. F.xplotab 
Recplici;.te lffi, Replicate z• 
Fig . 70 
( 
Discclution 1rcfileE. 
100 
S·C 
-0 
"' > 
0 50 
"' 
" 
.,... 
Q 
c 
OJ 
r.J 
... 
~ 
;.. 
10 
Jl.o:-c crb ic <·cid 2.5% 
['isfntegrant 2% 
SteEric ac1d Z.5% 
EmcompreEs aC: J.004 
Time in mi.m:.tes. 
Kooy: 
.EtrCOECoy 
A l. c-Df-Sol 
8 Explotab 
• Cc•rn Etard: 
Fig. 71 
164 
:o 
100 
90 
""' ., 
> 
0 
"' 
"' 50 ..... Q 
... 
c: 
., 
(J 
.... 
1J 
::>.. 
( 
Re.plicate J 
Key: ® Emcosoy 2% 
10 20 
Time in minutes. 
Dissolution profile for Ascorbic acid formulation containing 
27.of different disintegrants. 
Fig . 72 
165 
30 
166 
Re, pl ice: te 2 
"tJ 
.., 
;:. 
-.;; 
ill 
tJl 
ke.y; 
Q Emcc·soy 2% 
Q 
w ::. 
'"' 
" u 
... 
QJ 
::>. 
10 Time in ' 20 llll.nutes. 
_.Q 
Dissolutior' 1•rofile for Al!corbic c:cid fcrmulatioc cont.sini.n~ 2% C'f d:_fferer:t: 
disinresrarts;. 
( Fig. 73 
( 
100 
90 
~o 
> 
.... 
0 
"' 
"' ~Q 
u 
c 
OJ 
u 
... 
OJ 
"" 
167 
Rei:lic:c:tE J 
Key: 
A Ac-Di-Sol 2% 
10 20 30 
Time in minutes. 
DISSOLUTION PF.OFILE FOR P, SCORBIC AC.ID FORMULATION CCNTAINING 
2% OF DIFFEF.ENT DISINTEGRANTS. 
Fig. 74 
( ' 
100 
90 -
'..·O 
'U 
J) 
> 
..... 
.;, 
"' (}) 
.... 
Q 
.. 
= al 
v 
.. 
al 
~ 
Rei:licate 2 
K<cy: 
~ Ac-Di-Sol :l. "I· 
10 zo 
:'itte in mim;teE., 
Dissolutiot;. i;rcfile for Asc.c.rbl.c acid forn-ulation cc-ritaining ~iffe.rent 
disintegrant at 2~ le~el. 
Fig. 75 
168 
30 
169 
( 
Rep] ic<!te 
100 
90 
~ 
OJ 
;;. 
..... 
0 50 
"' 
"' .,... 
0 
.... 
c 
OJ 
u 
"' OJ ,,.. 
Key: 
It) Explotab 2% 
10 20 30 
Time in minutes. 
DISSOLUTION PROFILE FOR ASCORBIC ACID FORMULATION CONTAINING 
2% OF DIFFERENT DISINTEGRANTS. 
Fig. 76 
170 
( 
Feplic1'r:e 2 
lOC 
90 
( 
" 
50 
'1l 
> 
c 
'JI 
"' ..... Q 
... 
...: 
Iii 
" 
Key: 
... 
"' ....
I±] Explotab 2% 
lO Time in minute£. 20 3 
Dtssclution profile for Aecc·rbl.c ~c. ici formulation c.c•ntafning 2% of 
dif f erent disintegranrs . 
( 
Fig. 77 
( 
100 
90 
.:.o 
( 
Rq·licare 1 
Ke.y: 
@ Corn starch. 2% 
JO 20 
Time in minutes. 
DISSOLUl~ON PROFILE FOR ASCORBIC ACID FORMULATION CONTAINING 
2% OF DIFFERENT DISINTEGRANTS. 
Fig. 78 
30 
171 
172 
( 
100 Replic.ote 2 
90 
Key: 
(fJ Corn starch.~-/· 
.,,, 
.., 
:> 
~ 
( (; 0) 0) 
· ~ 
:::: so 
... 
"' ... u 
... 
CJ ,,.. 
10 :.o 
Time i.n lllinutes. 
Disf:clution i:rofile for Asc·ot·t ic zcid formulation con ta.in in~ 2% C'f different 
di.sinte5rant. 
Fig. 79 
( 
100 
SC 
"" 
"' ;> 
.... 
50 u 
"' 
"' <.:.: 
.... 
"' -:; u 
)... 
"' Po. 
Dis5clution Frofi1e~. 
10 
Fig. 80 
Fornula tiotl.: 
Ascorbic ac.i d 25% 
Disinte€,rarH. 3% 
Stearic acid 2.5% 
En1ccn1press c.d 100/~ 
Key: 
e En1cc·~cy 
• Corr.. : r.arcl: 
30 
173 
174 
( 
s 
.,,, 
OJ 5 :> 
( Q "' 
"' Ci 
.... 
~ 
.;; 
'..I 
.... 
0.. 
10 20 30 
Ojssclution ptcfile fer Af>corbic c:.cid fot"lI!ulation cor>tajning :?% Emcoscy 
Rf,plicate l~ , Rei:licate 2e 
Fig. 81 
( 
~ 
" ;>-
...... 
v 
"' 
"' ~ 
"" ( .. C; 
"' u 
... 
'l) 
""' 
100 
90 
50 
175 
10 J.nute~ 20 · 
f;jssolution profiles for .Ascc•rl:tc add formulation c.or:tafnjng 3:% C0rn starct 
Rei:licz.te I ~ , Replicate 2. 
Fig. 82 
( 
( 
176 
IV. CONCLUSION 
Emcosoy was tested for three major mechanisms of disintegration: 
(i) swelling, (ii) porosity and capillary action (wicking), and (iii) 
deformation. Swelling and wicking were adequate in the comparison of 
other satisfactory disintegrants, but Emcosoy had a poor plastic de-
formation. The viscosity of the gel produced by Emcosoy on wetting 
is less than the gel produced by CLD II, but higher than that by Ac-
Di-Sol. All these factors were considered separately; but in actual 
disintegration of a tablet, inter-relationships always take place. 
Proper storage precautions are advised for this disintegrant be-
cause it has a tendency to promote microbial growth in the presence of 
high moisture at room temperature as observed during the wetting and 
drying test. 
In this project, a total of 45 tablet formulations were studied, 
and about 100 dissolution profiles were obtained on various vitamin 
formulations using either Emcompress or Emdex as the tablet matrix. 
The results obtained clearly indicate that: 
1. Emcosoy is superior to corn starch as a tablet disintegrant 
at two or three percent levels; 
2. Emcosoy competes favorably with other disintegrants, such as 
Explotab and Ac-Di-Sol, at half, one, and two percent levels; 
3. Emcosoy demonstrates superior dissolution profiles when 
evaluated against other disintegrants in vitamin formulations; 
and 
( 
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4. Water-insoluble matrix is more helpful in the evaluation of 
different disintegrants. 
Emcosoy is demonstrably a powerful tablet disintegrant of natural 
source which deserves careful consideration by all formulators. 
( 
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V. SUGGESTIONS FOR FUTURE WORK 
Life is the sum of unfulfilled dreams. So is research -- there 
is always the nagging doubt that one could have done better. 
The author would have liked to change the particle size of Em-
cosoy to determine its effect on disintegration and other properties 
of the tablet. 
Emcosoy has one great advantage over other popular disintegrants 
in that it is of natural origin. If we want to retain this advantage, 
there is very little we can do to change its property. It would be of 
great advantage to reduce the proteinaceous fraction of Emcosoy 
composition (at present, about 17.5%) by some changes in processing 
procedure. The author anticipates that such changes would improve 
the plastic deformation of the Emcosoy particles; and consequently, 
the disintegration property. Low protein fraction would also help 
in protecting disintegrant at higher moisture level from lumping, 
as well as from microbial degradation. 
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VIII APPENDIX 
1. Computer Program For The Calculation Of Mean, Standard Deviation 
And Relative Standard Deviation 
100 
110 
120 
130 
140 
150 
160 
170 
180 
190 
200 
210 
220 
230 
240 
250 
260 
270 
280 
290 
300 
310 
320 
330 
340 
350 
360 
370 
380 
390 
REM --------------------------------------
REM I=COUNTER 
REM N=NUMBER READ 
REM S=SUM OF N 
REM T=SUM OF N SQUARED 
REM V=VARIANCE 
REM D=STANDARD DEVIATION 
REM R=RELATIVE STD, DEVIATION 
REM S/(I-l)=MEAN 
REM ---------------------------- ---------
LET I=O 
LET S=O 
LET T=O 
LET V=O 
LET D=O 
LET R=O 
FOR I=l TO 100 
INPUT N 
IF N=999 THEN 320 
LET S=S+N 
LET T=T+N**2 
NEXT I 
LET V=(T-(S**2/(I-l)))/(I-2) 
LET 
LET 
PRINT 
PRINT 
PRINT 
GO TO 
END 
D=V**.5 
R=(D/(S/(I-1)))*100 
"MEAN="·S/(I-1) 
, " 
"STANDARD DEVIATION= ;D 
"R.S.D.="; R 
200 
2. Computer Program For The Calculation Of Percentage Of Drug Dissolved 
100 DIMENSION TIME (30), ABS(30), CONG (30), AMT (30), TITLE (6) 
110 WRITE (6,155) 
120 155 FORMAT (//lX, 'ENTER THE NAME OF FORMULATION') 
130 READ (5,160) (TITLE (I), I=l,6) 
140 160 FORMAT (6A4) 
142 WRITE (6,112) 
144 112 FORMAT(//lX, 'ENTER TOTAL VOLUME OF DISSOLUTION MEDIUM') 
146 READ (5,*)TV 
150 WRITE (6,105) 
160 105 FORMAT (//lX, 'ENTER SLOPE OF BEERS PLOT (ABS/MCG PER ML)') 
170 READ (5,*) SLOPE 
180 100 FORMAT (//lX, 'SLOPE='Fl0.5) 
182 WRITE (6,117) 
184 117 FORMAT (//lX, 'ENTER DILUTION FACTOR') 
186 READ (5,*) D 
190 WRITE (6,115) 
200 115 FORMAT (//lX, 'ENTER NUMBER OF DATA POINTS') 
210 READ (5,*)N . 
( 
188 
220 WRITE (6,135) 
230 135 FORMAT (//lX, 'ENTER TOTAL THEREOTICAL AMOUNT OF DRUG IN MG') 
240 READ (5,*)TD 
250 WRITE (6,125) 
. 260 125 FORMAT (//lX, 'ENTER TIME, ABSORBANCE') 
270 READ(5,*) (TIME(I), ABS (I), I=l,N) 
280 WRITE (6,100) SLOPE 
290 DO 20 J=l,N 
300 CONC (J)= 0. 0 
310 20 CONTINUE 
320 TLCONC=O.O 
330 CORRX=O.O 
340 DO 25 I=l, N 
350 CONCX=O.O 
360 CONCX=(ABS(I)/SLOPE)*D 
370 TLCONO=TLCONC+cORRX 
380 CORRX=(CONCX*5.0)/TV 
390 CONC(I)=CONCX+TLCONC 
400 AMT(I)=(CONC(I)*TV)/1000.00 
410 25 CONTINUE 
420 WRITE(6,165)(TITLE(I), I=l,6) 
430 165 FORMAT(//1X,6A4) 
440 WRITE(6,190) 
450 190 FORMAT(//lOX, 'TIME(MIN)', 4X,'AMT(MG)' ,5X, 'PERCENT', 5X, 'PERCENT') 
460 WRITE(6,300) 
470 300 FORMAT(//33X, '(ACTUAL AMT)' ,2X, '(CLAIMED AMT)') 
480 DO 30 I=l,N 
490 PERCNT=(AMT(I)/AMT(N))*lOO 
500 CPRCNT=(ANT(I)/TD)*l00.00 
510 WRITE(6,250)(TIME(I),AMT(I),PERCNT,CPRCNT) 
520 250 FORMAT(//1X,4(3X,Fl0.2)) 
530 30 CONTINUE 
540 PD=(AMT(N)/TD)*l00.00 
550 WRITE(6,145)PD 
560 145 FORMAT(//lX, 'PERCENT OF DRUG IN TABLET=',Fl0.2) 
570 STOP 
580 END 
( 
Spectrophotometer Reading For 
Pyridoxine Hydrochloride (USP) 
Concentration(f<g/ml) 
14.50 
7.25 
3.63 
1.81 
Absorbance 
0.623 
0.304 
0.205 
0.153 
Spectrophotometer Reading For 
Ascorbic Acid (USP) 
Concentration(,kg/ml) 
14.10 
9.04 
7.05 
5.64 
Absorbance 
0.833 
0.567 
0.386 
0.303 
Spectrophotometer Reading For 
Granulated Ascorbic Acid (Roche) 
Concentration(~g/ml) 
17.7 
13.3 
8.8 
6.6 
Absorbance 
0.880 
0.735 
0.493 
0.374 
189 
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Beer's Plot For Pyridoxine Hydrochloride(USP) 
>. max=291 
Slope=.0373 
5 10 15 
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Beer's Plot Ascorbic Acid (USP) 
,.l max=244 nm 
Slope=.062 
5 10 15 
Concentration pg/ml. 
192 
l.O- Beer's Plot for Granulated Ascorbic Acid (Roche) 
,,\ max=244nm 
( 
Slope=.046 
.5 
5 10 . ,15 20 
Concentration /lg/ml. 
